BEFORE THE UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

PETITION TO CANCEL REGISTRATION OF PNR1427 INSECTICIDE (BRAND NAME SERESTO)

EPA REGISTRATION NO. 11556-155 (REGISTERED MAR. 16, 2012)

Summary by Full Reg.

Full Product Reg. #	rotell foc					BEDE	BC 88	
	75,385	666	1	1,698	3,767	40,087	7,743 21,439	

Summary by 11 Character Reg.

 Total Inc.									
75,385	666	1	1,698	3,767	40,087	7,743	21,439	0	

	le Description
DA	Domestic Animal - Fatality
DB	Domestic Animal - Major
DC	Domestic Animal - Moderate
DCDE	Domestic Animal - Moderate, Minor and Unknown
DD	Domestic Animal - Minor
DE	Domestic Animal - Unspecified
HD	Human - Minor
HE	Human - Unspecified
ONT	Other Nontarget

Reproduction from Aggregate Incident Summary Report for Seresto (June 16, 2020)

SUBMITTED BY: CENTER FOR BIOLOGICAL DIVERSITY APRIL 8, 2021



Via Electronic and Certified Mail

April 8, 2021

Michael Regan, Administrator U.S. Environmental Protection Agency 1200 Pennsylvania Ave. NW Mail Code: 1101A Washington, DC 20460 regan.michael@epa.gov

Michal Ilana Freedhoff, Acting Asst. Admin. Office of Chemical Safety and Pollution Prevention
U.S. Environmental Protection Agency
1200 Pennsylvanian Avenue, N.W.
Mail Code 7101M
Washington, DC 20460
freedhoff.michal@epa.gov

Edward Messina, Acting Director Office of Pesticide Programs U.S. Environmental Protection Agency 1200 Pennsylvania Ave. NW Mail Code: 7501P Washington, DC 20460 messina.edward@epa.gov

Re: Petition to Cancel Registration of PNR1427 (Brand Name Seresto) under the Federal Insecticide, Fungicide, and Rodenticide Act; Reg. No. 11556-155

Dear Administrator Regan, Acting Assistant Administrator Freedhoff, and Acting Director Messina,

Pursuant to the right to petition the government provided in the First Amendment to the U.S. Constitution¹ and the Administrative Procedure Act,² the Center for Biological Diversity—on behalf of itself and its 1.7 million members and supporters and their beloved companion

_

¹ See U.S. Const. Amend. I; see also United Mine Workers v. Ill. State Bar Ass'n, 389 U.S. 217, 222 (1967) (explaining that the right to "petition for a redress of grievances [is] among the most precious of the liberties safeguarded by the Bill of Rights").

² See 5 U.S.C. § 553(e).

animals—hereby petitions the U.S. Environmental Protection Agency (EPA) to cancel its registration of insecticide product PNR1427, more commonly known by its brand name Seresto; Registration No. 11556-155. This product, which is registered under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) for use on adult dogs and puppies and on adult cats and kittens for the purpose of flea and tick treatment, poses a severe risk to the animals on which it is used and to human health. According to a recent aggregate incident summary report, since this product was introduced in 2012, EPA has received over 75,000 adverse incident reports, including at least 1,698 reports linking the use of this product to pet deaths and at least 700 involving human harm.³ Because these harms amount to significant unreasonable adverse effects under FIFRA, cancellation of this product is not only warranted but essential for protecting public health, consumers, imperiled wildlife, and companion animals. In the interim pending complete cancellation of the product, EPA should take additional steps to suspend Seresto's registration.

I. PETITIONER

The Center for Biological Diversity (Center) is a non-profit environmental organization dedicated to the protection of native species and their habitats through science, policy, and environmental law. The Center has more than 1.7 million members and online activists dedicated to the protection and restoration of endangered species and wild places. For over 30 years, the Center has worked to protect imperiled plants and wildlife, open space, air and water quality, and overall quality of life. The Center's Environmental Health Program and Pesticides Reduction Campaign aim to improve pesticide regulation in order to reduce the harms of pesticides to the environment, human populations, and threatened and endangered species.

II. ACTION REQUESTED

Because of the dangers posed by Seresto to threatened and endangered species, companion animals, and people, the Center hereby petitions EPA to:

- (1) Cancel registration number 11556-155 pursuant to FIFRA § 136d(b); and
- (2) Suspend Seresto's registration pending completion of cancellation proceedings pursuant to FIFRA § 136d(c)(1).

III. LEGAL AND FACTUAL BASIS FOR PETITION

a. Federal Insecticide, Fungicide, and Rodenticide Act

FIFRA, 7 U.S.C. § 136 *et seq.*, provides the framework for the federal regulation of pesticide distribution, sale, and use. The law is intended to prohibit the use of pesticides that cause unreasonable adverse effects on the environment.⁴ The Administrator of the EPA is responsible for carrying out the mandates of the Act. Pursuant to this obligation, the Administrator may limit the use of certain pesticides to prevent unreasonable adverse effects.⁵

⁴ 7 U.S.C. § 136a(a).

³ See Exhibit A.

⁵ *Id.* §§ 136a(c)(5)-(6).

FIFRA defines a "pesticide" as "any substance or mixture of substances intended for preventing, destroying, repelling, or mitigating any pest[.]" When a pesticide is sold or distributed, it is generally referred to as a "pesticide product." FIFRA generally prohibits the sale or distribution of a pesticide product unless it has first been "registered" under FIFRA Section 3 by EPA.⁷

EPA "issues a license, referred to as a 'registration,' for each specific pesticide product allowed to be marketed; the registration approves sale of a product with a specific formulation, in a specific type of package, and with specific labeling limiting application to specific uses." In order for the EPA to evaluate an application for pesticide registration, an application must "describ[e] how the pesticide will be used, the claims made of its benefits, the ingredients, and a description of all tests and studies done and the results thereof, concerning the product's health, safety, and environmental effects."

FIFRA Section 3(c)(5), "Approval of Registration," provides that EPA can register a pesticide only if the agency determines that:

- (A) its composition is such as to warrant the proposed claims for it;
- (B) its labeling and other material required to be submitted comply with the requirements of this subchapter;
- (C) it will perform its intended function without unreasonable adverse effects on the environment; and
- (D) when used in accordance with widespread and commonly recognized practice it will not generally cause unreasonable adverse effects on the environment.¹⁰

The term "unreasonable adverse effects on the environment" is further defined as "any unreasonable risk to man or the environment, taking into account the economic, social, and environmental costs and benefits of the use of any pesticide." When EPA applies this risk-benefit balancing test, it may only register a pesticide if it finds that the risks associated with the use of a pesticide are justified by the benefits of such use. ¹² In order to remain registered, a pesticide must continue to meet this risk-benefit standard, which EPA may reassess at any time. ¹³

⁶ *Id*. § 136(u).

⁷ *Id.* § 136a(a).

⁸ 69 Fed. Reg. 47,732, 47,733 (Aug. 5, 2004).

⁹ Pollinator Stewardship Council v. EPA, 806 F.3d 520, 523 (9th Cir. 2015).

¹⁰ 7 U.S.C. § 136a(c)(5).

¹¹ *Id.* § 136(bb); *see also id.* §§ 136a(a), 136a(c)(5)(c).

¹² Washington Toxics Coal. v. Envtl. Prot. Agency, 413 F.3d 1024, 1032 (9th Cir. 2005) (explaining that FIFRA uses a "cost-benefit analysis to ensure that there is no unreasonable risk created for people or the environment from a pesticide.").

¹³ *Id.* at 1033 (The "EPA retains discretion to alter the registration of pesticides for reasons that include environmental concerns." (citing 7 U.S.C. §§ 136d(c)(1)-(2), 136(l)); *see also Nat. Res. Defense Council v. Johnson*, 422 F. Supp. 2d 105, 109 (D.D.C. 2006) ("The EPA uses numerous types of review processes to periodically reevaluate a registered pesticide's risks and benefits." (citing *Beyond Pesticides/Nat'l Coal. Against the Misuse of Pesticides v. Whitman*, 294 F. Supp. 2d 1, 3 (D.D.C. 2003)).

After an applicant submits sufficient data for pesticide registration, EPA may grant "unconditional registration" under § 136a(c)(5). "Unconditional registration necessarily requires sufficient data to evaluate the environmental risks." ¹⁴ If an applicant has not submitted sufficient data to support unconditional registration, EPA may conditionally register the pesticide under certain limited circumstances. ¹⁵

A pesticide product remains registered until EPA or the registrant cancels it pursuant to FIFRA Section 6. ¹⁶ Under Section 6, if it appears to EPA that a registered pesticide has "unreasonable adverse effects on the environment" when "used in accordance with widespread and commonly recognized practice," then EPA may undertake cancellation proceedings. ¹⁷ Any interested person may petition EPA to cancel a registered pesticide product. ¹⁸ EPA is required by the Administrative Procedure Act to resolve the petition "within a reasonable time." ¹⁹

b. Seresto Product Registration

EPA registered insecticide product PNR1427, more commonly known by its brand name Seresto, for use on March 16, 2012. The product was unconditionally registered in accordance with FIFRA Section 3(c)(5) for use on adult cats and kittens above 10 weeks of age, as well as adult dogs and puppies above 7 weeks of age.²⁰ The product, which is dispensed in the form of a pet collar fastened around the neck, is intended to repel and kill ticks for 8 months, including deer ticks, blacklegged ticks, American dog ticks, brown dog ticks, Lone Star ticks, fleas, flea larvae, and lice.²¹ The registration number for this product is 11556-155.

c. Seresto Active Ingredients

Seresto is made up of a plastic band impregnated with insecticides that are released over time to coat the animal's fur.²² It contains as active ingredients the neonicotinoid imidacloprid (10%) and the pyrethroid flumethrin (4.5%).²³ Understanding each of these ingredients, alone and in combination, is important for understanding the toxicity and risks that their use in Seresto presents to dogs, cats, humans, and exposed threatened and endangered species.

¹⁴ Pollinator Stewardship Council, 806 F.3d at 523; see also 7 U.S.C. § 136a(c)(5) (listing the findings required for unconditional registration).

¹⁵ See 7 U.S.C. § 136a(c)(7).

¹⁶ *Id.* § 136d.

¹⁷ *Id.* § 136d(b).

¹⁸ 40 C.F.R. § 154.10; Washington Toxics Coal. v. EPA, 413 F.3d at 1033.

¹⁹ 5 U.S.C § 555(b).

²⁰ EPA, Notice of Pesticide Registration, Reg. No. 11556-155 (2012),

https://www3.epa.gov/pesticides/chem_search/ppls/011556-00155-20120316.pdf.

 $^{^{21}}$ *Id*.

²² See EPA, Weighing Risks to Children from Dogs Wearing Seresto Collars (2016), https://www.epa.gov/sites/production/files/2017-

^{01/}documents/weighing risks to children from dogs wearing seresto-tm collars.pdf. ²³ Id.

i. Imidacloprid

Imidacloprid is a neonicotinoid pesticide. Neonicotionoids are understood to produce neuronal toxicities in insects via a common mechanism of action, that being the disruption of acetylcholine/nAChR signaling. According to EPA, "[i]midacloprid [is] in the N-nitroguanidine group of neonicotinoids (IRAC subclass 4A) along with clothianidin, thiamethoxam and dinotefuran. Its mode of action on target insects involves out-competing the neurotransmitter, acetylcholine for available binding sites on the nAChRs. At low concentrations, neonicotinoids cause excessive nervous stimulation and at high concentrations, insect paralysis and death will occur."²⁴

Neonicotinoids like imidacloprid are most well-known for the harms they cause to pollinator species, including threatened and endangered pollinators like the Poweshiek skipperling (endangered), Dakota skipper (threatened), and rusty patched bumble bee (endangered). These species are often exposed to neonicotinoids through a broad array of non-intended exposure pathways, including through agricultural and household uses of the pesticide. Laboratory studies have demonstrated that the neonicotinoid imidacloprid is, for example, "highly toxic to bumble bees." Even sub-lethal exposure in bumble bees results in "reduced food consumption, reproduction, worker survival rates, and foraging activity." Neonicotinoids are also toxic to solitary native bees such as blue orchard and alfalfa leafcutter bees, with direct effects including increased mortality rate with direct contact, as well as other native pollinators.

Studies also confirm that small doses of imidacloprid can negatively affected the ability of songbirds to navigate.³⁰ This is especially concerning for birds that may eat an imidacloprid-treated seed or other coated product, since consumption can cause direct mortality as well as sub-

²⁴ EPA, Preliminary Terrestrial Risk Assessment to Support the Registration Review of Imidacloprid, at 11-12 (2017), https://www.regulations.gov/document/EPA-HQ-OPP-2008-0844-1256.

²⁵ 79 Fed. Reg. 63,672, 63,737 (Oct. 24, 2014); Szymanski, J., et al., *Rusty Patched Bumble Bee (Bombus affinis) Species Status Assessment* (2016), https://ecos.fws.gov/ServCat/DownloadFile/120109.

²⁶ Jennifer Hopwood, et al., The Xerces Soc'y for Invertebrate Conservation, *Are Neonicotinoids Killing Bees*?, at vi (2012), http://cues.cfans.umn.edu/old/pollinators/pdf-pesticides/Are-Neonicotinoids-Killing-Bees_Xerces-Society.pdf; see also Barraud, A., et al., *The Impact of Pollen Quality on the Sensitivity of Bumblebees to Pesticides*, 105 Acta Oecologica 103552 (2020); Whitehorn, P. R., et al., *Neonicotinoid Pesticide Reduces Bumble Bee Colony Growth and Queen Production*, 336 Science 351–352 (2012); Feltham, H., Park, K., Goulson, D., *Field Realistic Doses of Pesticide Imidacloprid Reduce Bumblebee Pollen Foraging Efficiency*, 23 Ecotoxicology 317–323 (2014).

²⁷ Jennifer Hopwood, et al., The Xerces Soc'y for Invertebrate Conservation, *Are Neonicotinoids Killing Bees*?, at vi (2012), http://cues.cfans.umn.edu/old/pollinators/pdf-pesticides/Are-Neonicotinoids-Killing-Bees_Xerces-Society.pdf.

²⁸ *Id.* at 15.

²⁹ Christoph Sandrock et.al., *Sublethal Neonicotinoid Insecticide Exposure Reduces Solitary Bee Reproductive Success*, 16 Agricultural & Forest Entomology 119 (2014), https://beyondpesticides.org/assets/media/documents/pollinators/documents/Sandrocketal2013 Subletha Ineonicexposurereducessolitarybeereproductivesuccess AgricForEnt.pdf.

³⁰ Margaret Eng, et al., *Imidacloprid and Chlorpyrifos Insecticides Impair Migratory Ability in a Seed-Eating Songbird*, 7 Scientific Reports 15176, DOI:10.1038/s41598-017-15446-x (2017).

lethal effects, with a leading concern being harm to reproduction.³¹ According to a 2017 EPA Preliminary Terrestrial Risk Assessment of imidacloprid, a large bird (> 1kg) would only need to eat *one* imidacloprid-treated potato seed to nearly exceed the risk of concern for acute harm and possible death.³²

While most frequently associated with agricultural crop uses, imidacloprid is also the most common neonicotinoid used in household products, including flea and tick treatments such as Seresto. According to public records obtained from EPA by the Natural Resources Defense Council (NRDC), over the past decade there have been at least 1,630 recorded imidacloprid poisoning incidents in humans that are attributable to these uses.³³ The reported symptoms include skin rash, muscle tremor, difficulty breathing, vomiting, wheezing, lock jaw, memory loss, and renal failure.³⁴

This follows closely with EPA's own findings about the health risks of imidacloprid to mammals—the class of vertebrates that includes humans, cats, and dogs. "The nervous system is the primary target organ of imidacloprid." In early human health risk assessments of imidacloprid, EPA scientists noted a number of toxic effects in oral studies of rats and mice (surrogates for humans) from dietary exposure to imidacloprid. These effects included decreased movement and body weights, tremors, thyroid effects, retinal atrophy, and brain effects. The second return of the second

Hitting even closer to concerns related to the use of imidacloprid as an active ingredient in Seresto, in a 2017 risk assessment EPA noted that dogs were more sensitive to imidacloprid than the standard test animals (*e.g.*, rats and mice), even at doses seven times lower than the level of

³¹ See Ertl, H. et al., Potential Impact of Neonicotinoid Use on Northern bobwhite (Colinus virginianus) in Texas: A Historical Analysis, PLoS ONE 13:e0191100 (2018),

https://doi.org/10.1371/journal.pone.0191100; Millott et al., Field Evidence of Bird Poisonings by Imidacloprid-Treated Seeds: A Review of Incidents Reported by the French SAGIR Network from 1995 to 2014, Environ Sci Pollut Res, DOI 10.1007/s11356-016-8272y (2016); Lopez-Antia et al., Risk Assessment of Pesticide Seed Treatment for Farmland Birds Using Refined Field Data, 136 Environmental Research 97 (2015).

³² EPA, Preliminary Terrestrial Risk Assessment to Support the Registration Review of Imidacloprid, (2017), https://www.regulations.gov/document/EPA-HQ-OPP-2008-0844-1256.

³³ EPA, FOIAOnline, Request No. EPA-HQ-2019-004044 (2019), https://foiaonline.gov/foiaonline/action/public/submissionDetails?trackingNumber=EPA-HQ-2019-004044&type=request; see also NRDC, Neonicotinoid Pesticides: Potential Risks to Brain and Sperm (Jan. 6, 2021), https://www.nrdc.org/experts/jennifer-sass/neonic-pesticides-potential-risks-brain-and-sperm#:~:text=Imidacloprid%20is%20the%20most%20common,by%20EPA%20(see%20here).

³⁴ Id.

³⁵ EPA, Preliminary Health Effects Division Risk Assessment for Imidacloprid, at 13 (2003), https://www3.epa.gov/pesticides/chem_search/cleared_reviews/csr_PC-129099_4-Mar-03_111.pdf. ³⁶ Id.

 $^{^{37}}$ *Id*.

toxicity for mice and rats.³⁸ The neurotoxic effects consisted of severe tremors and trembling at mid- to high-doses.³⁹ Acute oral toxicity studies in dogs were not further discussed.

The studies reviewed by EPA in generating these human health assessments were based on industry-generated studies and did not include the many published, peer-reviewed studies that have shown toxic effects in mammals from exposure to imidacloprid. The state of California, however, also conducted a human health risk assessment for imidacloprid that took a deeper look at the science around harms to health related to imidacloprid exposure through dietary and drinking water routes. That assessment, conducted by the California Environmental Protection Agency, emphasized that acute oral exposure of rats and mice to imidacloprid produced clinical signs that are similar to nicotine intoxication, including tremors, decreased coordination and mobility, spasms, respiratory difficulties, and lethargy. Even further, in longer term toxicity studies (subchronic and chronic), rats exposed to imidacloprid experienced body weight reductions. In the subchronic studies, the liver was the principal target organ with necrosis or toxic injury occurring in the liver. Additional effects noted in these studies included degeneration of the testes, atrophy of the thyroid gland and bone marrow, and effects on the thymus. In the chronic toxicity studies, reduction in body weight was a common toxic effect along with thyroid lesions in rats.

In the two dog oral studies reviewed by California toxicologists, toxic effects from exposure to imidacloprid were observed in the liver, testes, thyroid, bone marrow, and thymus. ⁴⁵ Severe tremors were also reported in these studies. ⁴⁶ No cat-specific studies were analyzed.

For humans, the California assessment also specifically identified pregnant women or women of childbearing age as a high-risk group, finding that: "[e]vidence from the developmental neurotoxicity study in rats, suggested that imidacloprid may affect the neural development. The estimated NOEL for decreases in dimensions of brain structures was 5.5 mg/kg/day. This ENEL might be pertinent to acute exposures of women of childbearing age to protect for fetal exposure. Based on the ENEL of 5.5 mg/kg/day, the acute dietary MOEs for females 13-49 yrs. would be 366 at the 95th and 239 at 99th percentiles, which exceed the general health protective benchmark MOE of 100."⁴⁷ Further, and more generally, the assessment identified that:

Several human neuropathologies have been linked to genetic alterations of nAChRs genes or autoimmune disruption of the receptor proteins, including congenital

³⁸ EPA, Imidacloprid: Human Health Draft Risk Assessment for Registration Review, at 11-12 (2017), https://www.regulations.gov/document?D=EPA-HQ-OPP-2008-0844-1235.

³⁹ *Id.* at 14.

⁴⁰ Cal. EPA, Imidacloprid: Risk Characterization Document; Dietary and Drinking Water Exposure, at ix (2006), https://www.cdpr.ca.gov/docs/risk/rcd/imidacloprid.pdf.

⁴¹ *Id*.

⁴² *Id*.

⁴³ *Id*.

⁴⁴ Id.

⁴⁵ *Id*. at 61.

⁴⁶ Id.

⁴⁷ Id. at xii.

myasthenia, autosomal dominant frontal lobe nocturnal epilepsy and possibly a schizophrenic syndrome. These receptors are also involved at various degrees in several neuropathologies such as Parkinson and Alzheimer's diseases, and Gilles de la Tourette's syndrome. Autoimmune responses to specific neuronal nAChR subunits have been found in the skin disease pemphigus, in which cells of the epidermis lose adherence.⁴⁸

Furthermore, a systematic review of peer-reviewed literature on human health effects of neonicotinoids reported a link between neonicotinoid exposures and malformations of the developing heart and brain, as well as a cluster of symptoms including memory loss and finger tremors. For example, the review discussed a study by National Institute of Health-funded researchers from University of North Carolina at Chapel Hill and University of California, Davis that associated frequent exposure to imidacloprid applied as flea and tick treatments for pets (Advantage by Bayer) during pregnancy with a 2-fold elevated risk of autism spectrum disorder in prenatally-exposed children. For

ii. Flumethrin

The other active ingredient found in Seresto pet collars, at 4.5%, is flumethrin. Flumethrin is a pyrethroid insecticide, which is in a class of pesticides that—like neonicotinoids—target insects' peripheral and central nervous systems.⁵¹ These chemicals are some of the most widely used pesticides in the United States, both in agricultural and residential settings.⁵² Dependency on pyrethroids has increased over the past twenty years, propelled by interest in replacing organophosphate insecticides.⁵³ Today, pyrethroids and pyrethrins are so heavily used that their environmental concentrations exceed regulatory thresholds.⁵⁴

Until recently, pyrethroids were believed to have limited toxicity in humans; this belief was based on the assumption that they are rapidly metabolized by the human body. But current studies and scientific investigations cast serious doubt on that assumption. For example, one recent pharmacokinetic study on the pyrethroid deltamethrin indicates that its peak concentration in the human brain is two times higher than that in rats.⁵⁵ Additionally, mammalian studies showed that repeated exposure to low levels of a pyrethroid insecticide caused learning

⁴⁹ Cimino, et al., *Effects of Neonicotinoid Pesticide Exposure on Human Health: A Systematic Review*, 125(2) Environmental Health Perspectives 155 (2017), https://ehp.niehs.nih.gov/doi/full/10.1289/EHP515.

⁴⁸ *Id.* at 3-4 (citations omitted).

⁵⁰ Id. at 160 (citing Keil, et al., Autism Spectrum Disorder, Flea and Tick Medication, and Adjustments for Exposure Misclassification: the CHARGE (CHildhood Autism Risks from Genetics and Environment) Control Study, 13 Environ. Health 3 (2014), https://pubmed.ncbi.nlm.nih.gov/24456651/).

⁵¹ T.G.E. Davies et al., *DDT*, *Pyrethrins*, *Pyrethroids and Insect Sodium Channels*, 59 LIFE 151, 155 (2007).

⁵² Muhammad M. Hossain, et al., *Hippocampal ER Stress and Learning Deficits Following Repeated Pyrethroid Exposure*, 143 Toxicological Sciences 220, 220 (2015).

⁵³ Holly A Rogers, et al., *Bifenthrin Causes Trophic Cascade and Altered Insect Emergence in Mesocosms: Implications for Small Streams*, 50 Envtl. Sci. & Tech. 11,974, 11,974 (2016). ⁵⁴ *Id.*

⁵⁵ Stephen J. Godin, et al., *Physiologically Based Pharmacokinetic Modeling of Deltamethrin:* Development of a Rat and Human Diffusion-Limited Model, 115 Toxicological Sciences 330, 338 (2010).

deficiencies and physiological effects associated with neurodegeneration, Alzheimer's, and Parkinson's diseases, among others.⁵⁶ Even further, one study revealed higher incidences of autism spectrum disorders and developmental delay amongst children whose mothers were living within 1.5 kilometers of sites of pyrethroid applications during the third trimester of pregnancy.⁵⁷

EPA's 2012 human health risk assessment of flumethrin for use in cat and dog collars indicates that it has toxic effects similar to many other pyrethroids. These effects include pawing, burrowing, writhing, salivation, coarse tremors, decreased body weights, and impaired motor activity. While a later 2018 human health risk assessment for flumethrin did not find risks of concern, it showed that the relevant toxicity studies were conducted on rats and mice rather than dogs or cats (the animals that the manufacturer of flumethrin was seeking approval for its use on), making it difficult to determine the actual toxic effects of flumethrin on dogs and cats. 60

Further, according to a 2019 risk assessment of flumethrin, EPA identified that between 2013 and 2018 there were at least 907 incidents reported for humans. The assessment further determined that there were 19 severe incidents, with the most often reported symptoms being dermal (8 total) and neurological (7 total). Of the 8 people that experienced dermal incidents, the symptoms reported included rashes, skin lesions, and hives; of the 7 people that experienced neurological incidents, the symptoms reported included numbness, headaches, and seizures.

A sampling of the incidents listed in that 2019 risk assessment include:

- A 12-year-old boy who slept in a bed with a dog wearing a collar started having seizures and vomiting. He had to be hospitalized.⁶⁴
- A 67-year-old woman who slept in a bed with a dog wearing a collar reported having heart arrhythmia and fatigue. 65
- A 43-year-old man put collars on eight dogs and slept in the same bed as four of the dogs. A week later, he developed ear drainage and nasal and throat irritation and was told by a

⁵⁶ Muhammad M. Hossain, et al., *Hippocampal ER Stress and Learning Deficits Following Repeated Pyrethroid Exposure*, 143 Toxicological Sciences 220, 220 (2015).

⁵⁷Janie F. Shelton, et al. Neurodevelopmental Disorders and Prenatal Residential Proximity to Agricultural Pesticides: The CHARGE Study, 122 Children's Health 1103, 1107 (2014).

⁵⁸ See generally EPA, Flumethrin: Human Health Risk Assessment for the Section 3 Registration Action for Cat and Dog Collars (2016), https://www.regulations.gov/document?D=EPA-HQ-OPP-2016-0031-0005.

⁵⁹ *Id*. at 5.

⁶⁰ EPA, Flumethrin: Draft Human Health Risk Assessment for Registration Review (2018), https://www.regulations.gov/document?D=EPA-HQ-OPP-2016-0031-0027.

⁶¹ EPA, Flumethrin: Tier I Update Review of Humane Incidents and Epidemiology for Proposed Interim Decision, at 3-4 (2019), https://www.regulations.gov/document/EPA-HQ-OPP-2016-0031-0031.

⁶² Id. at 4.

⁶³ *Id*.

⁶⁴ *Id.* at 8-9.

⁶⁵ *Id.* at 8.

doctor that he had a hole in his ear drum. He removed the dog collars and the symptoms went away. He later reapplied the collars and the symptoms returned. 66

Not only do pyrethroids present serious risks to the health of humans, dogs, and cats, but they also present risks to wildlife resources and ecosystems. A study by U.S. Geological Survey scientists found that commonly used pyrethroids have the potential to "alter aquatic and terrestrial ecosystem function at the regional scale."67 More specifically, the study concluded that pyrethroid contamination in freshwater streams resulted in "less abundant and less diverse macroinvertebrate communities."68 Additionally, the study revealed that pyrethroid contamination in aquatic ecosystems "propagate across life stages and generations of invertebrates, trophic levels in aquatic food webs, and ecosystem boundaries to riparian food webs."69 Indeed, in its recent aquatic risk assessment for 20 pyrethroids and pyrethrins, EPA did an analysis on many of the home uses of this pesticide class and found significant risks to aquatic invertebrates from just the indoor uses alone. 70

The Synergistic Action of Imidacloprid and Flumethrin iii.

Since imidacloprid and flumethrin do not exist in isolation in the Seresto product, their synergistic effects must also be taken into consideration. "Synergy" is the mixing of pesticide ingredients with other pesticides and chemicals before application (or after), and the ways in which the individual ingredients can interact in the mixture in a way that enhances their toxic effects. These synergies, which are generally not assessed by EPA when it approves a pesticide product and specifically were not assessed in its approval of Seresto, 71 can turn what would normally be considered a safe level of exposure to people, wildlife, and the environment into one that causes considerable harm.⁷² However, even published studies by the original manufacturer of Seresto, Bayer, have shown that the combination of imidacloprid and flumethrin produces synergistic action in dogs and cats that may make these two chemicals more powerful and more toxic together than each individual pesticide alone.⁷³

⁶⁶ Id.

⁶⁷ Holly A Rogers, et al., Bifenthrin Causes Trophic Cascade and Altered Insect Emergence in Mesocosms: Implications for Small Streams, 50 Envtl. Sci. & Tech. 11,974, 11,974 (2016). ⁶⁸ *Id.* at 11,979.

⁶⁹ Id. at 11,980.

⁷⁰ EPA, Preliminary Comparative Environmental Fate and Ecological Risk Assessment for the Registration Review of Eight Synthetic Pyrethroids and the Pyrethrins, (2016), https://www.regulations.gov/document/EPA-HQ-OPP-2010-0384-0045.

⁷¹ EPA, Weighing Risks to Children from Dogs Wearing Seresto Collars (2016), https://www.epa.gov/sites/production/files/2017-

^{01/}documents/weighing risks to children from dogs wearing seresto-tm collars.pdf ("The risk of the combination of the two active ingredients, flumethrin and imidacloprid, was not assessed ").

⁷² Nathan Donley, Center for Biological Diversity, Toxic Concoctions: How the EPA Ignores The Dangers of Pesticide Cocktails, 1 (2016),

https://www.biologicaldiversity.org/campaigns/pesticides_reduction/pdfs/Toxic_concoctions.pdf.

⁷³ Stanneck, et al., The Synergistic Action of Imidacloprid and Flumethrin and Their Release Kinetics From Collars Applied for Ectoparasite Control in Dogs and Cats, 5 Parasites & Vectors 73 (2012), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361670/.

Even further, as it relates to these two pesticides, recent research published by the journal *Science* has determined that neonicotinoids and pyrethroids have driven an increase in the toxicity of pesticides to aquatic invertebrates and pollinators, even as effects have generally fallen for vertebrates.⁷⁴ As summarized by the researchers who conducted the study, "[o]ur results challenge the claims of a decrease in the environmental impacts of pesticide use."⁷⁵

IV. STATEMENT OF LEGAL GROUNDS

FIFRA provides the legal framework for federal regulation of pesticide use, sale, and distribution. The law is intended to prohibit the use of pesticides that cause unreasonable adverse effects on the environment. EPA, the recipient of this petition, is responsible for carrying out the mandates of the Act. As identified through Exhibits A-C and *supra* in Section III (b) – (c), evidence exists that past and present uses of Seresto have caused unreasonable adverse impacts upon the environment and present an imminent hazard. The harms caused by Seresto use are not outweighed by the benefits of continued use. Therefore, pursuant to its obligations under FIFRA, EPA must cancel registration number 11556-155 pursuant to Section 136d(b) in order to prevent any additional unreasonable adverse effects on the environment, and, pending completion of cancellation proceedings, must suspend Seresto's registration pursuant to Section 136d(c)(1).

a. Seresto Must be Cancelled for Causing an "Unreasonable Risk" to Man and the Environment in Violation of FIFRA

Cancellation of a pesticide product's registration is warranted where the pesticide, "when used in accordance with widespread and commonly recognized practice, generally causes unreasonable adverse effects on the environment," including "any unreasonable risk to man or the environment." Here, the registration of Seresto must be cancelled because its continued use as a flea and tick collar for dogs and cats—which is the use for which is has been approved, and is therefore appropriately identified as use "in accordance with widespread and commonly recognized practice"—is causing unreasonable adverse effects on members of the public, imperiled species, and companion animals.

According to a recent aggregate incident summary report, since Seresto was introduced in 2012, EPA has received over 75,000 adverse incident reports on this product, including at least 1,698 reports linking the use of this product to pet deaths and nearly 700 involving harm humans.⁷⁷ In addition, use of the collar has caused rashes, seizures, motor dysfunction, fatigue, diarrhea, vomiting, and excessive drooling in animals.⁷⁸ According to Karen McCormack, a former

⁷⁴ Schulz, *Applied Pesticide Toxicity Shifts Toward Plants and Invertebrates, Even in GM Crops*, 372 Science 81-84 (2021), https://science.sciencemag.org/content/372/6537/81.

⁷⁵ Marc Heller, Farm Chemicals Turning More Toxic for Wildlife, E&E News (Apr. 1, 2021), https://www.eenews.net/eenewspm/stories/1063729071/feed.

⁷⁶ 7 U.S.C. § 136d(b); *see also id.* § 136(bb) (providing that "[t]he term 'unreasonable adverse effects on the environment' means (1) any unreasonable risk to man or the environment, taking into account the economic, social, and environmental costs and benefits of the use of any pesticide").

⁷⁷ See Exhibit A.

⁷⁸ Jimy Tallal, Seresto Flea Collar Linked to 1,700 Pet Deaths, The Malibu Times (Mar. 26, 2021), http://www.malibutimes.com/news/article_36818990-8db8-11eb-9bt9-cf20318319cf.html; see also

pesticide researcher, policy analyst, environmental fate scientist, and communications specialist for EPA, Seresto collars "have the most incidents of any pesticide product she's ever seen."⁷⁹

For comparison, in 2009 NRDC petitioned EPA to cancel all pet uses for the pesticide tetrachlorvinphos (TCVP) due to the risks it posed to the health of children and because EPA relied on a faulty health assessment in approving its use in flea collars and powders. ⁸⁰ In 2020, in response to a legal challenge brought by NRDC against EPA's for its delay in responding to the 2009 petition, the Ninth Circuit Court of Appeals issued a decision highlighting the gravity of these risks and finding that "[r]epeatedly, the EPA has kicked the can down the road and betrayed its prior assurances of timely action, even as it has acknowledged that the pesticide poses widespread, serious risks to the neurodevelopmental health of children." Yet, even in that case the number of incidents related to the use of TCVP (approximately 4,600, including 363 deaths, between 1992 and 2008) paled in comparison to those being reported for Seresto (75,000, including almost 1,700 deaths). ⁸²

Further, in the case of TCVP, one of the primary concerns expressed in that petition was that:

These products are designed to leave chemical residues on a pet's fur. Children playing with their cat or dog get these residues on their hands, where the chemical can be absorbed through the skin or ingested when they put their hands in their mouths—and young kids, especially toddlers, put their hands in their mouths a lot. When we redid the calculations, we found that these vulnerable children could be exposed at levels that put their developing brains at risk. 83

The exact same exposure pathway (and suite of concerns) exists with regards to pesticide exposure for children and other humans that come into contact with a companion animal wearing a Seresto collar. In fact, when used "in accordance with widespread and commonly recognized practice," Seresto "gradually releas[es] a consistent low-dose of its active ingredients . . . once the collar comes in contact with your pet's skin or coat. The active ingredients diffuse into the lipid (fatty/oily) layer of your pet's skin and fur and cover your pet within 24 hours." Once in place, the collar then "remains effective for eight months at a time," meaning that the potential for a child or other person to be exposed to its active ingredients (for example, through petting,

Exhibit B (National Pesticide Information Center Reports to EPA); Exhibit C (MedWatch Veterinary Incident Reports).

https://www.advantagepetcare.com.au/au/parasites/fleas/how-do-seresto-flea-collars-work/.

⁷⁹ Jonathan Hettinger, *Popular Flea Collar Linked to Almost 1,700 Pet Deaths. The EPA Has Issued No Warning*, USA Today (Mar. 2, 2021),

 $[\]frac{https://www.usatoday.com/story/news/investigations/2021/03/02/seresto-dog-cat-collars-found-harm-pets-humans-epa-records-show/4574753001/.$

⁸⁰ NRDC, Petition to Cancel All Tetrachlorvinphos (TCVP) Pet Uses (Apr. 23, 2009), https://www.regulations.gov/document/EPA-HQ-OPP-2009-0308-0002.

⁸¹ NRDC v. United States EPA (In re NRDC), 956 F.3d 1134, 1136 (9th Cir. 2020).

⁸² EPA, Tetrachlorvinphos: Animal Incident Summary (Feb. 3, 2009),

https://www.documentcloud.org/documents/20491417-epa-hq-opp-2008-0316-0018 pet-poisoning.

⁸³ NRDC, No More Poisons on Pets: The EPA Must Act (May 29, 2019),

https://www.nrdc.org/experts/miriam-rotkin-ellman/no-more-poisons-pets-epa-must-act,

⁸⁴ Advantage Petcare, How Do Seresto Flea Collars Work? (Feb. 2021),

kissing, snuggling, sleeping, or other contact—affections common between people, and especially children, and their companion animals) is also sustained over a long period of time, lasting up to eight months. And there can be no question that these impacts on human health are significant here since approximately 700 of the adverse incident reports for Seresto involved harm to humans. 86

For the animals themselves, this also means that exposure to the active ingredients in Seresto is chronic since the collar is designed for the consumer to "buy it, put it on and then forget about it for months." For example, while the product label indicates that the collar is for external use only, that direction does not account for the fact that dogs and cats frequently clean themselves (by, for example, licking their fur), and can ingest the collar's pesticides in so doing. As identified *supra* in Section III (c), such exposure can lead to a variety of unreasonable and harmful effects in the animals, the significance of which is underscored by the product's stunning 75,000 adverse incident reports and staggering almost 1,700 pet deaths.

In addition, to the extent animals wearing the Seresto collar are washed or otherwise sluff the collar's active ingredients into the surrounding environment—for example through rolling or other activities, those active ingredients can come into contact with wildlife, including federally protected threatened and endangered species, and further place those already imperiled species at a greater risk of extinction. For example, as identified *supra* in Section III (c), uses of imidacloprid are directly implicated in declines of rusty patched bumble bee populations, a species that is listed as endangered under the federal Endangered Species Act. ⁸⁸

Finally, the harms caused by Seresto use are not outweighed by the benefits of continued use because numerous proven effective methods exist for treating fleas and ticks on companion animals that do put the animal's health, or the health of exposed humans and wildlife, at risk. These alternatives include oral flea-prevention treatments, frequent grooming, and use of nontoxic flea and tick shampoos.⁸⁹

In sum, considerable evidence exists that past and present uses of the pesticide product Seresto are causing unreasonable adverse impacts on the environment, including "unreasonable risk[s] to man," companion animals, and threatened and endangered species. Because these harms are significant and ongoing, cancellation of this product is not only warranted by EPA but essential for protecting public health, consumers, imperiled wildlife, and companion animals.

⁸⁵ *Id*.

⁸⁶ See Exhibit A.

⁸⁷ LA

⁸⁸ See, e.g., Szymanski, J. et al. Rusty Patched Bumble Bee (Bombus affinis) Species Status Assessment (2016), https://ecos.fws.gov/ServCat/DownloadFile/120109.

⁸⁹ See, e.g., NRDC, Nontoxic Ways to Protect Your Pet (Jan. 22, 2016), https://www.nrdc.org/stories/nontoxic-ways-protect-your-pet.

b. <u>Immediate Suspension of Seresto's Registration Pending Cancellation is</u> Warranted

Suspension of a pesticide's registration is warranted under FIFRA § 136d(c)(1) when such action is necessary to prevent an imminent hazard⁹⁰ during the time required for cancellation.⁹¹ The term "imminent hazard" is defined as "a situation which exists when the continued use of a pesticide during the time required for [a] cancellation proceeding would be likely to result in unreasonable adverse effects on the environment or will involve unreasonable hazard to the survival of a species declared endangered or threatened." Here, as documented *supra* in Sections III(b) – (c) and IV(a), both of these situations exist (ongoing and imminent unreasonable adverse effects on the environment *and* unreasonable hazard to the survival of the endangered rusty patched bumble bee, as well as other imperiled pollinators). ⁹³

Quick action from EPA to remove this product from the market is also a matter of substantial public concern. The significant harms associated with the use of this product have sparked a public outcry, 94 retailers considering whether they should discontinue sale of the product, 95 and a federal Congressional request to the manufacturer of Seresto to voluntarily recall the collars (the

⁹⁰ 7 U.S.C. § 136(1) ("The term 'imminent hazard' means a situation which exists when the continued use of a pesticide during the time required for cancellation proceeding would be likely to result in unreasonable adverse effects on the environment").

⁹¹ *Id.* §136d(c)(1) ("If the Administrator determines that action is necessary to prevent an imminent hazard during the time required for cancellation ... the Administrator may, by order, suspend the registration of the pesticide immediately.").

⁹² *Id.* § 136(1).

⁹³ See also Envtl. Defense Fund, Inc. v. EPA, 510 F. 2d 1292, 1297 (D.C. Cir. 1975) (upholding an EPA suspension and cancellation order for aldrin and dieldrin and stating: "We have cautioned that the term 'imminent hazard' is not limited to a concept of crisis. 'It is enough if there is a substantial likelihood that serious harm will be experienced during the year or two required in any realized projection of the administrative process." (citing Envtl. Defense Fund, Inc. v. EPA, 465 F.2d 528, 540 (D.C. Cir. 1972)); EPA, E.I. du Pont de Nemours and Company Imprelis Order (Aug. 11, 2011),

https://www.epa.gov/enforcement/e-i-du-pont-de-nemours-and-company-imprelis-order (EPA order under FIFRA to E.I. DuPont de Nemours (DuPont) directing the company to immediately cease the distribution, sale, use or removal of Imprelis herbicide products under its ownership, control, or custody because "[t]he directions for use and/or warning or caution statements on DuPont's Imprelis labeling are inadequate to protect non-target species.").

⁹⁴ Jonathan Hettinger, *Popular Flea Collar Linked to Almost 1,700 Pet Deaths. The EPA Has Issued No Warning*, USA Today (Mar. 2, 2021),

https://www.usatoday.com/story/news/investigations/2021/03/02/seresto-dog-cat-collars-found-harm-pets-humans-epa-records-show/4574753001/; CBS New York, *Questions Raised About Safety of Popular Seresto Flea Collar* (Mar. 24, 2021), https://newyork.cbslocal.com/2021/03/24/seresto-pet-collar-safety-concerns/.

⁹⁵ Jonathan Hettinger, *Amazon is Reviewing Best-Selling Seresto Flea Collar After Report of Illnesses, Deaths*, USA Today (Mar. 5, 2021),

https://www.usatoday.com/story/news/investigations/2021/03/05/amazon-reviewing-seresto-flea-collar-amid-reports-illnesses-deaths/4586990001/.

manufacturer declined to do so). 96 In furtherance of the public interest and the objectives of FIFRA, the registration for Seresto should, therefore, be suspended pending cancellation proceedings to prevent an imminent hazard to human health and companion animals, and to protect threatened and endangered species.

V. CONCLUSION

For the forgoing reasons, Petitioner the Center for Biological Diversity requests that, pursuant to its obligations under FIFRA, EPA cancel registration number 11556-155 (Seresto) pursuant to Section 136d(b) to prevent additional unreasonable adverse effects on the environment, and, pending completion of cancellation proceedings, suspend Seresto's registration pursuant to Section 136d(c)(1). As the government agency that has assumed the responsibility of lawfully managing pesticide product registrations in a way that does not harm the environment and human health, EPA can and must do better. The Center urges EPA to act on this petition without delay.

Sincerely,

Hannah M.M. Connor

Senior Attorney

Center for Biological Diversity

P.O. Box 2155

St. Petersburg, FL 33731

Phone: (202) 681-1676

hconnor@biologicaldiversity.org

Lori Ann Burd Environmental Health Director Center for Biological Diversity P.O. Box 11374 Portland, OR 97211

Phone: (971) 717-6405

laburd@biologicaldiversity.org

Enclosures

⁹⁶ Jonathan Hettinger, *House Subcommittee Seeks Voluntary Recall of Seresto Flea and Tick Collars*, Midwest Center for Investigative Reporting (Mar. 18, 2021),

https://investigatemidwest.org/2021/03/18/house-subcommittee-seeks-voluntarily-recall-of-seresto-flea-and-tick-collars/.

EXHIBIT A

Total Rows Returned: 48 Aggregate Incident Summary Report by Product Report Date & Time: 06/16/2020 2:46:00 PM GN

Reg No. Selected 100 011556-00155

Reporting Date Pance 01/01/2012 To 06/16/2020 All a a n M Package and Full Product To tal m m 8) Ĝ m M 80) G Accidental temperatura 011556-00155 SERESTO CAT Impregnated 024671-00008 Materials 024968-00005 011556-00155 SERESTO LARGE Impregnated DOG Materials SERESTO 025109-00007 011556-00155 Impregnated Materials **SERESTO** 025472-00010 011556-00155 Impregnated Materials **SERESTO** 025767-00009 011556-00155 Impregnated 1,661 1,074 Materials 011556-00155 **SERESTO** 1,076 026184-00005 Impregnated Materials 011556-00155 **SERESTO** 026494-00002 Impregnated C Materials 011556-00155 SERESTO 1,896 1,319 026745-00008 Impregnated Materials **SERESTO** 1,303 011556-00155 2,028 027067-00012 Impregnated Materials 027348-00007 011556-00155 **SERESTO** Impregnated 1,301 Materials 011556-00155 **SERESTO** 027609-00005 Impregnated Materials 011556-00155 **SERESTO** Impregnated 3,265 2,296 027876-00012 Materials 011556-00155 **SERESTO** 3,507 2,370 n 028098-00010 Impregnated Materials 011556-00155 SERESTO 2,221 1,421 028336-00008 Impregnated Materials 028777-00004 011556-00155 SERESTO Impregnated 1,456 Materials 011556-00155 **SERESTO** 4,076 2,970 029069-00009 Impregnated Materials 011556-00155 SERESTO LARGE 029169-00002 Impregnated DOG Materials 011556-00155 SERESTO Impregnated 3,015 029308-00008 4,417

Materials

Total Rows Returned: 48 Aggregate Incident Summary Report by Product Report Date & Time: 06/16/2020 2:46:00 PM GN

				J J																	00, 10	, =0=0			
Package and Sag #	Fall Product Res. #	Product Name	Form	Fotel Sec												G				5				0.00	
029600-00007	011556-00155	SERESTO	Impregnated Materials	2,488	15	0	54	239	0	600	1,580	0	0	0	0	0	0	0	0	0	0	0	0	0	0
029843-00005	011556-00155	SERESTO	Impregnated Materials	1,697	15	0	54	159	1,118	351	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
030205-00008	011556-00155	SERESTO	Impregnated Materials	4,101	34	0	92	208	3,767	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
030491-00009	011556-00155	SERESTO	Impregnated Materials	4,564	24	0	87	350	4,103	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
030703-00006	011556-00155	SERESTO	Impregnated Materials	3,011	21	0	86	299	2,605	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
030964-00006	011556-00155	SERESTO	Impregnated Materials	1,490	18	0	63	157	1,252	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
031245-00008	011556-00155	SERESTO	Impregnated Materials	4,381	35	0	12 5	226	3,995	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
031516-00012	011556-00155	SERESTO	Impregnated Materials	5,247	40	0	14 8	102	4,958	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
031728-00008	011556-00155	SERESTO	Impregnated Materials	3,019	24	0	81	21	2,893	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032053-00003	011556-00155	SERESTO	Impregnated Materials	1,669	25	0	70	13	1,561	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032333-00010	011556-00155	SERESTO	Impregnated Materials	4,651	44	0	15 1	30	4,426	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032632-00008	011556-00155	SERESTO	Impregnated Materials	31	2	0	2	0	27	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032632-00009	011556-00155	SERESTO	Impregnated Materials	1,157	7	0	14	2	1,134	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032632-00010	011556-00155	SERESTO	Impregnated Materials	168	4	0	8	2	154	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032632-00011	011556-00155	SERESTO	Impregnated Materials	2,511	10	0	24	14	2,463	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032632-00012	011556-00155	SERESTO	Impregnated Materials	3	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032632-00013	011556-00155	SERESTO	Impregnated Materials	1,476	6	0	4	5	1,461	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032924-00004	011556-00155	SERESTO	Impregnated Materials	14	2	0	0	0	12	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032924-00005	011556-00155	SERESTO	Impregnated Materials	668	5	0	12	3	648	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032924-00006	011556-00155	SERESTO	Impregnated Materials	117	5	0	4	0	108	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032924-00007	011556-00155	SERESTO	Impregnated Materials	1,231	11	0	9	3	1,208	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Total Rows Returned: 48 Aggregate Incident Summary Report by Product Report Date & Time: 06/16/2020 2:46:00 PM GN

									9									5						-	
Participe and Sag 3	Fall Product Reg. #	Product Name	Form	Total Inc.						0.0			144 E		i i	0.6	0.0		W	8					5
032924-00008	011556-00155	SERESTO	Impregnated Materials	3	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
032924-00009	011556-00155	SERESTO	Impregnated Materials	693	6	1	12	2	672	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
033132-00006	011556-00155	SERESTO	Impregnated Materials	11	1	0	1	0	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
033132-00007	011556-00155	SERESTO	Impregnated Materials	502	2	0	6	1	493	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
033132-00008	011556-00155	SERESTO	Impregnated Materials	80	1	0	4	1	74	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
033132-00009	011556-00155	SERESTO	Impregnated Materials	602	6	0	9	3	584	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
033132-00010	011556-00155	SERESTO	Impregnated Materials	3	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
033132-00011	011556-00155	SERESTO	Impregnated Materials	361	5	0	3	3	350	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
033132-00012	011556-00155	SERESTO CAT	Impregnated Materials	3	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Summary by Full Reg.

Full Product Reg. #		HD H	5 67.	DE DEDE DE	0.0	91	9111	GC DWB DW	GWB GWC SWB SWB PDB	PIDIC
8815556400155	75,385	666 1	1,698	3,767 40,087 7,743	21,439 0	0 0	0 0	0 0 0	0 0 0 0 0	0

Summary by 11 Character Reg.

11 Char Reg. #	Total Table	HD	HE	3/4	06	DEDE	0.0	919	0.0	413	213	61.5	C C	ec	3348	23340		GW				200	Diete
	75,385	666	1	1,698	3,767	40,087	7,743	21,439	0	0	0	0	0	0	0	0	0	0	C	1	0	0	0

	e Description
DA	Domestic Animal - Fatality
DB	Domestic Animal - Major
DC	Domestic Animal - Moderate
DCDE	Domestic Animal - Moderate, Minor and Unknown
DD	Domestic Animal - Minor
DE	Domestic Animal - Unspecified
DWB	Drinking Water - Moderate

Total Rows Returned: 48 Aggregate Incident Summary Report by Product Report Date & Time: 06/16/2020 2:46:00 PM GN

Exposure	
Severity Code	Description
DWC	Drinking Water - Minor
GB	Groundwater - Moderate (with possibly mixed types of water)
GC	Groundwater - Minor (with possibly mixed types of water)
GWB	Groundwater - Moderate
GWC	Groundwater - Minor
HD	Human - Minor
HE	Human - Unspecified
ONT	Other Nontarget
РВ	Plant Damage - Minor
PDB	Property Damage - Moderate
PDC	Property Damage - Minor
PL	Plant Lawn
SWB	Surface Water - Moderate
SWC	Surface Water - Minor
WB	Wildlife - Minor

EXHIBIT B



LOG: 3159

Veterinary Pesticide Adverse Effects Reporting http://npic.orst.edu/vet

An additional mode of reporting adverse effects is by contacting the manufacturer. Under FIFRA 6(a)(2), manufacturers are required to submit adverse effects information about their products to the U.S. EPA. From your email, it sounds like the manufacturer may have been Bayer - Bayer appears to have a phone number specifically for their Bayer Animal Health division. If you haven't contacted them directly, you may consider calling them to report this issue. Their number, as well as additional manufacturer contact information can be accessed from the following link (alphabetical order):

http://npic.orst.edu/ingred/manuf.htm


Again, please contact us at 800-858-7378, Monday - Friday from 8:00am to 12:00pm PT. We look forward to answering any questions you have, and documenting your situation further.

Possible product information (per NPIRS database): active ingredient flumethrin and imidacloprid.

Inquirer sent follow up email with photos of cat's hair loss; no further incident details provided. Provided information to EPA, Executive Committee and Project Coordinator.




LOG: 3159





LOG: 3159





LOG: 10548

Date: November 9, 2016

City, State: WINSTED, CT

Caller wanted to report 2 of her 5 dogs had a reaction to a Seresto Collar, EPA registration number 11556-155 (active ingredients imidacloprid, flumethrin). Caller reported six days ago (11/3/2016) she used a collar on each dog. Caller reported having 3 small dogs on which she used Seresto Small Dog and 2 bigger dogs on which she used Seresto Large Dog. Caller reported 5 days after the application her 2 bigger dogs had a reaction to the collar. Caller reported one dog (2 year old, English Bulldog, male, neutered, 55 pounds) had a seizure 5 days after application (11/8), has a bleeding sore near the top of its head right were the collar was, and its eyes are bright red and irritated. Caller reported her other big dog (14 year old, 55 pounds, female, spayed, American Bulldog) started shaking all over and urinated all over itself, 3 to 4 hours after the first dog had a seizure. Caller reported one of the smaller dogs (Mini Dachshund, 7.5 year old, male, neutered, 20 pounds) keeps scratching by the collar. Caller reported the other 2 dogs (both 7 years old, 7 pounds, female, Maltipoo) are fine and caller reported there were no symptoms. Caller reported she used the collars because they were recommended by the veterinarian. Caller reported the veterinarian told her to use the large collar, for dogs over 18 pounds, for the big dogs and the small collar, for dogs under 18 pounds for the others. Caller reported after her two dogs had a reaction she removed all the collars from her pets. Caller reported she also wanted to complain about the label having conflicted information, because it claims it is better than monthly use products but at the same time it says people cannot sleep with the pet if it is wearing a collar and to not let children touch a pet wearing a collar, "which implies the product is toxic". Discussed NPIC services, including role as a pesticide health and safety information resource and discussed not having legal or regulatory authority. Discussed that NPIC incident reports are made available to the U.S. EPA. Discussed that an additional mode of reporting adverse effects is by contacting the manufacturer. Discussed that under FIFRA 6(a)(2), manufacturers are required to submit adverse effects information about their products to the U.S. EPA. Provided contact information for manufacturer. Discussed ways to minimize exposure, including option of asking for next steps or asking about potential benefit of bathing the dogs. Resources used: Inchem and ATSDR, Toxicological Profile for Pyrethrins and Pyrethroids - 2. Relevance to Public Health.



LOG: 8944

Date:

October 2, 2017

City, State: St. Louis, MO

Narrative: Caller (age 63) seeking information on how long her reaction to a Seresto Flea Collar (active ingredients flumethrin, imidacloprid) may last, and wants to report her reaction. Caller reported that she applied a collar to her two cats and small dog 9 days ago, and by the next evening her lips and tongue were swollen, her eyes were beginning to swell, she had tingling and burning inside her mouth and on her lips, and she had blisters form inside her mouth. Caller reported she picks up and carries her dog frequently throughout the day, and each time she picks it up she kisses it on the head. Caller reported that it took several days before she realized that the collar was the only thing that had changed in the house, and she removed the collars four days after she had put them on.

Caller reported she called the manufacturer (Bayer Healthcare) on the day she removed the collars, was told that in rare cases people do have these reactions, was advised to use vitamin E on her skin, and to shampoo the animals. Caller reported she washed all of the animals that day. Caller reported that the next day (four days ago) she went to the urgent care, was given a steroid shot and a 5-day supply of steroids, and was told to not use the vitamin E oil. Caller reported that the swelling has gone down, but the tingling and burning on her lips and mouth are still present, and it has influenced her ability to eat and has a hard time eating anything with salt because it burns. Caller reported there were no symptoms for any of her animals from the collars. Caller reported she has since returned the collars and their packaging back to the store where she bought them.

Discussed NPIC services, including the inability to provide medical treatment advice. Discussed risk equation concepts, including toxicity and routes of exposure. Discussed the toxicity of the active ingredients, and reported symptoms from exposure to them (NPIC Fact Sheet, "Inchem UKPID Monograph Flumethrin", & "NY DEQ Human Health Assessment Flumethrin - 2012"). Discussed providing the Recognition and Management of Pesticide Poisonings to her medical provider as a resource for toxicology information on active ingredients, and provided NPIC website.



LOG: 7313

Date:

August 1, 2016

City, State: Johnson City, NY

Narrative: Caller wishing to report a reaction her dog (100 lb, 8 year old, intact male German shepherd) had to a dog collar, EPA registration number 11556-155 (active ingredients imidacloprid, flumethrin). Caller reported that she applied the collar to the dog on 06/29/2016, that he lives in an outdoor kennel, and that she noticed the next morning that the dog was shaking his head more than normal, but her husband had an accident that kept her from paying much attention to the dog for quite awhile. Caller reported that on 07/12/2016 she was visiting the dog in his outside kennel, touched his head and ears and noticed that they were very hot and felt like they were "on fire". Caller reported that she called her veterinarian, and was told to check the dog's neck to see if he had sores, and if he did to remove the collar and bathe him. Caller reported that the dog did have noticeable oozing sores on his neck, she washed him with Dawn dish soap, and the veterinarian prescribed antibiotics and steroids to help with the inflammation without a clinic visit.

Caller reported that she took the dog into the veterinarian on 07/19/2016 because his symptoms seemed to continue, and the vet shaved the dog around his neck and down to his shoulder blades because the sores covered that entire area. Caller reported that the dog had an ear infection also, and was prescribed another antibiotic, and another cream ointment. Caller reported that she has been using a medicated shampoo on the dog, and has had to move him indoors while he has open wounds on his skin. Caller reported that she that she has been incredibly disappointed with the response of the manufacturer (Bayer Healthcare) to her situation. Caller reported she is planning on doing everything she can to try to stop other consumers from going through a similar experience.

Discussed NPIC services. Discussed the registration of products through both federal and state agencies, and provided contact information for the State Lead Pesticide Agency as a resource for reporting concerning pesticides. Resources used: Registration Decision for Flumethrin for Use in Cat and Dog Collars - 2012, NPIC Fact Sheet, & Hazardous Substances Data Bank (HSDB).

EXHIBIT C

U.S. Department of Health and Human Services

A BOV ATCH

The FDA Safety Information and Adverse Event Reporting Program

A PATIENT INFORMATION

20684-1

In Confidence

single best answer)

Hispanic/Latino

Not Hispanic/Latino

1. Check all that apply

Death Include date (dd-mmm-yyyy):

M Hospitalization – initial or prolonged Other Senous (Important Modical Events)

LL- 02-2016 5. Describe Event, Problem or Product Use Error

3. Date of Event (ad-mmm-yyyy)

Overnight.

R Adverse Event

Life-threatening

5.3, Ethnicity (Check

approviation, and 4-digit year, for example, 01-Jul-2015.

2. Age

Note: For date prompts of "dri-mmm-yyyy" please use 2-digit day, 3-letter month

or Date of Birth (e.g., 08 Feb 1925)

23-12-2010

B ADVERSE EVENT PRODUCT PROBLEM

Outcome Attributed to Adverse Event (Check all that apply)

Year(s) Month(s)

☐ Weck(s) ☐ Days(s)

5 b. Race (Check all that apply)

Product Use Error Problem with Different Manufacturer of Sums Medicine

Required Intervention to Prevent Pannanem Impairment/Damage (Devices)

Seresto collar for large dogs applied to pet. developed

Tremois in pelvic limbs

15 K/W, monorates is 1.90 K/W,

Scrumchemistry-normal value

on prednisens + cephalexin P.O.

Screstofleacollar for large doss

2. Product Available for Evaluation? (Do not send product to FDA)

1. Name, Manufacturer/Compounder, Strength (from product label)

6. Relevant Tests/Laboratory Data, Inclyding Dates

PCV/TS: 50%/8.19/11

O PRODUCTAVAIDABILIDA

∭ No

#1 - Hame and Strength

#2 - Name and Strength

Bayer

#1 - Manufacturer/Compound

depression and mild muscle

Other Relevant History, Including Proexisting Medical Conditions (e.g. allergies, preprancy, snoking and alechol use, iveritidney problems, etc.)

Collar was part of a treatment for, flea allege dermatitis pet also starked

Returned to Manufacturer on (dd-mmm-yyyy)

#1 - NDC # or Unique ID

AHNLO98T

#2 - Lot #

#2 - NDC # or Unique ID

AHNLO63TLA

CBC- teckocaptosis(18.67 Klav): ncutophilia

Asian American Indian or Alaskan Native

Black of African American White Native Hawaiian or Other Pacific Islander

Product Problem (e.g., defects/maifunctions)

For VOLUNTARY reporting of adverse events, product problems and product use errors

Page 1 of 3"

4. Welaht

113.6

(⊠ ib

☐ Female

X Male

Disability or Permanent Damage

Congenital Anomaly/Birth Defects

17-02-2016

4. Date of this Report (do-mmo-yyyy)

Dose or Amount

45a

4. Dates of Use (From/7

11/02/

5. Diagnosis or Reason

Flea allere

House Flear

#1 Tyes K No

Yes No

B. Expiration Date (dd-mmm-yyyy)

8, is this a single-use device that was

reprocessed and reused on a patient?

9 If Yes to Item 8, Enter Name and Address of Reprocessor

FOTHER (CONCOMITANT) MEDICAL PRODUCTS

6. Is the Product

3

Compounded?

Form Approved: OMB No. 0910-0291, Expires: 9/30/2018 See PRA statement on reverse. FDA USE ONLY Triage unit sequence # FDA Rec Date 44/208								
Frequency	loute							
Continuous	Topical							
'o for each) (If unknown, estimate) (dd-mmm-yyyy)	9, Event Abaled After Use Stopped or Doss Reduced?							
) (2	#1 Yes No Doesn't							
n for Use (Indication)	#2 Yes No Doesn't							
) Y	10. Event Reappeared After Reintroduction?							
officstation	#1 Tyes No & Coesai's							
7. Is the Product Over- the-Counter?	#2 Tyes No Doesn't							
#1 Tyes No	apply							
#2 Tyas No								

Common Device Nam	ė.	CTU	2b. Procode
. Manufacturer Nome, (City and State	MAR - 8 20°	ľ
, Model #	Lot#		5. Operator of Device
ajalog #		Date (cd-mmm-yvyy)	Lay User/Patient
ă lahe	Unique Ide	ntifier (UDI) #	Other
i. If Implanted, Give Da	te (dd-mmm-yyyy)		ilve Data (dd-mmm-yyy)

Product names and therapy dates (E	
prednisone 20mg	SID
cophalexin 500mg d	2, Caps 81P
G. REPORTER (See confiden	
1, Namp and Address	
Last Name: HARRISON	First Name EUEN
Addiess: CALVERT ANIX	
ON: ()(J)NGS	State/Province/Resion: [//, [)
Cauntry.	ZiP/Pestal Code®
Phone #:	Small,
<u> </u>	NGTIAN Manufacturer/
e se in a serve in a serve in the server in the serv	disclosed I Think the star

FORM FDA 3500 (10/15)

#2 - Manufacturer/Compounder

Submission of a report does not constitute an admission that medical personnel or the product caused or contributed to the event

to the manufacturer, please mark this box:

Distributor/Importer

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Center for Veterinary Medicine

VETERINARY ADVERSE DRUG REACTION, LACK OF EFFECTIVENESS, OR PRODUCT DEFECT REPORT (For VOLUNTARY Reporting)

FORM FDA 1932a (10/13)

1 0	•			910-064
(See ma:				/30/2016 latement
(See mai	iler page	e for Bu	ırden S	tatement

area series.				

NOTE: This report is authorized by 21 U.S.C 352 (a) and (f). V assure comprehensive and timely assessment of product labels	Vhile you are not required to report, your cooperation is needed to ing.
Individual Case Safety Report Number (FDA Assigned Number)	Submission Type
Report Type Adverse Event Product Problem	Both Adverse Event and Product Problem
Date of this Report (mm/dd/yyyy) (18)	Date of Initial Report (If this report is a follow-up) (mm/dd/yyyy)
Month 07 Day 18 Year 2016	
Nouth 01 Day 18 Year 3010	Month Day Year
	nformation
First Name	Last Name
Katie	Mayberger
Street Address 14 School St City RonKonKoma State or Pre	
City State or Pri	
	NY 11779
Country Telephone USA 51-	Number (Other) 487-9994 Telephone Number (Other)
Fax Number Fmail Adds	200
nur	se Katie 16 Egmail, com
bender Category	3
☐ Veterinarian ☒ Animal Own	
Other Health Care Professional	Other Unknown
Sender Previously Reported to the Manufacturer? X Yes	☐ No
If Yes, provide the Manufacturer's Case Number: 18663	314
No Identity Disclosure	dentity disclosed to the manufacturer, mark this box.
Preferred Method of Contact 💢 Telephone 💢 Emai	either
Health Care Professional Informati	on (If different from Sender Information)
First Name	Last Name RECEIVED
Atlantic Coast Veterinary	1.5020101151.5
Street Address 3250 Veterans Highway	
City State or Pro	vince Postal/ZIP Code
Bohemia	11716
Country Telephone	
	285-7780
Fax Number Email Addn (031) 285-778)56
	, ,

Page 1

PSC chaphics (Pri 1447-1997 EF

	***************************************	***************************************		
***************************************	on (If different from Sender I	nformation)		
First Name	Last Name			
Ole and Addition				
Street Address				
City	State or Province	10 41710 0		
Only .	State of Province	Postal/ZIP Code		
Country	Telephone Number	Telephone Number (Other)		
·	reichtione Mattibet	relephone Number (Other)		
Fax Number	Email Address			
Name of Suspected Product	ected Product Informatiom			
Seresto Colla	R - Small don			
Diagnosis and/or Reason for Use of the Product	91/10(11/309			
Flea & tick prevention				
•				
Dosage Form (Chewable, liquid, tablet, topical, injectio	n, etc.)			
collap				
(01,001				
Date of First Exposure (mm/dd/yyyy)	Date of Last Exposu	ure (mm/dd/yyyy)		
Month 0.7 Day 08 Year 201	A Mont	Month 07 Day 16 Year 2016		
Duration of Product Use				
~ 9 days				
	nformation for Suspected	Dradent		
Dose Administered	montation of Suspected i	riousci		
1 collar-size small		•		
Interval of Administration (Frequency)				
Worn continuously				
Route of Administration				
Collar Hopical				
Product Administered By		<u> </u>		
☐ Veterinarian/Veterina	ry Staff 🔀 Owner	Other		
Lot Number	Expiration Date (mr.	m/dd/yyyy) unknown at present		
KPOAEZO	Mont			
Name of Manufacturer of Suspected Product		• 1		
Bayer				
				
FORM FDA 1932a (10/13)	Page 2			

		Adverse E		mation		
Veterinarian's Level	of Suspicion that Product Caus					
3		Medium	*****] Low	Unknown	
Stavitad, mi	e Event (Describe briefly) CE on to Ring	c, Chemis	itry, IV	Fluids	, Valium drip	Controvous IV, Keppra
	Abate After Stopping the Produc	:1?	Did Advers	se Event Re	appear After Reintrod	luction of the Product?
X Yes	☐ No ☐ Not Ap	plicable	Yes			Not Applicable
Outcome	X Recovered ☐ Died	Other				
	Spo	cies and R	lelated In	formation		
Budgerigar	☐ Cat	Ca	ittle		Cockatiel	Cockatoo
∑ Dog	Ferret	☐ Fis	sh		Goat	Guinea Pig
Horse	Human	∏ Pa	rrot] Pig	Rabbit
Sheep	Other (Specify):			·		
Breed				Gender	Male	Female
Havane	Se				Male Neutered	Female Neutered
Age: 9 year	S		Weight:	15 IL)5	
	Overall Health	Status Wh	en Suso	ected Pro	duct Given	***************************************
ξΛ.		***************************************			er of Animals Treated	,
Excellent	Good Fair	Poor	Critical		er of Animals Affected	
		\dverse Ev				3333
Date of Onset of Adv	erse Event (mm/dd/yyyy)	· · · · · · · · · · · · · · · · · · ·				
		Month 07	Day 16	Year 2	016	
	een First Exposure to) and Onset of Adverse Event				veen Last Administra	
~ 9 da					s) and Onset of Adve	ies after administrat
	vent Occurred, Treatment with	Susperted Pr		Cint (.h)	umaaasy or	icz adler morra usi wi
Had already be		is discontinue		 Was disc	continued and replace	d with another product
Was discontinue	ed and reintroduced later		· ·		tinued at an altered d	·
Other (Specify):			~			
		***************************************	***************************************	***************************************		
Altached Document I	Name (Filename if Electronic)	Documen	t informa	tion		
THOUTHOU DOSSITION	service (i memeritae ii Erecci orac)					
Attached Document (Description	***************************************				<u> </u>
Attacked December 1 *	Harris (C2) (CE)					
waaneo Document (Name (Filename if Electronic)					
Attached Document (Description					
Attached Document h	Name (Filename if Electronic)	······				
Attached Document (Description		***************************************	•		15
FORM FDA 1932a (1	ก/13)	5.45 Contraction of the Contraction of the Contract	200 °	000000000000000000000000000000000000000		
·	44;	P	age 3			}

	Concurrent Clinical	Problem/c\	
Were There Concurrent Clinical Problems?	~~·>~~	· · · · · · · · · · · · · · · · · · ·	
Yes	⊠ No	Do not know	None
List Concurrent Clinical Problem(s).			
NA			
Concurrent Product	t Information /Fyclu	ding Treatment of Curre	ont Evanti
Please provide name(s), dose(s), interval(s), d that the patient was taking at the time of the excopies of this form) or provide comments in the	ate(s) of treatment(s), rent. Either copy this se	and other relevant informa action as needed (you may	tion to describe other products
Were Concurrent Products Given?	N. 4		
[] Yes	X No	Do not know	None
List Names of Concurrent Products Administered			
/			
Date of First Exposure (mm/dd/yyyy)	Date	e of Last Exposure (mm/dd/)	/ууу)
Month Day Year		Month D	ay Year
Duration of Product Use			
Adverse	Event/Product Prof	olem (Long Narrative)	
The state of the s			120
previously healthy dog with	i no medical	history, broug	is for annual physica
Describe the Adverse Event/Product Problem. Previously healthy dog with 2 weeks Prior with norma	I exam & hla	and work stools	specimen. Seresto
alla care with him	C CAMP TOP	alvicit Ball	alter anicontion.
collar recommended by y	et at Pimaci	al VISI7 107 14	La Stranta Collab
Dig was groomed Thursdo	يع ١٦١١١ و	coat was cut >	north screens consider
Collar recommended by your Dog was groomed Thursday 18116 pc	rinstruction	s. Ilialu-1/131	116, 4 FETTE 31919 V
log acted very nervous, o	nxious, hyp	per reoponalve	,7114116 - 113116 dog
vas lethargie, not herself aturday, woke up as usi	. Sleptalld	ay in an unu	sal location. 7/16/16,
vas letilorgio, in in an uni	ial had not	gotten up, not	ced the dog trying to
aturday, work of	n it well	a hortanoul S	cant white Frame
ear/clean teeth on Eside of	y mouth wir.	de la sura an	was rapid repeatable
arroadings hoticad un luwor	~ Janoi india		. eta do d tramocina.
ecreations noticed on lower an the "gum chewing" move	ements stopp	ed a entire body	Juliane Manny Strang
and the growth of Pi	cked the doo	Jup & the cor	vaisions became sing
called for my monding	log became i	idgid, apric, el	100 reverent the vace
more severe, or than hear	an gasping,	trying to move	air wouccesstury.
ian the "gum chewing" move called for my mother, Pi more severe, vet called, confiner head. She than begins than started breathing FORM FDA 1932a (10113)	a, her bodu re	laxed, she initio	ally couldn't stand or
THE MAN STATES OF COUNTY		\$	
FORM FDA 1932a (10/13)	Page 4		

Adverse Event/Product Problem (Long Narrative, Continued)

If more space is needed, continue description below of the Adverse Event/Product Problem. support herself. The collar was removed & she was brought to the vet immediately. She was back to normal upon arrival to the vet, still slightly over anxious, labs drawn with normal results & we returned home being advised just to monitor her as she never had this or any issue before. About 10:30pm the same night (7/16/16, Saturday) she presented with another seizure-gum chewing - full body convulsions & than it broke. This episode lasted ~ 15-30 seconds. The first flargest seizure lasted ~2-3 min in entirety and started at about 1030 Am of that morning (7/10/16). After looking online I read about washing her neck off with down detergent + water, as there are many similar stories of neurological issues after starting Seresto, specifically in Smaller breeds. Dogs neckline was cleaned off ~ 113pm that night. At 1230 how Sunday morning a 3rd seizure occurred, gum chewing, = confusion discriented | scarred > convulsion) > fell over on side > gasping for air. After regaining concloweress she was weak, confused, howling, running around the house, appearing lost. This last episode lasted 1-2 mun. She was rushed to Vet ER & admitted until Sunday (7/17/16) right. Upon arrival she was onewed & again, back to herself. Her admission was uneventful, & seizure activity, vital signs stable, Chemistries ICBC normal. She was started on a Valium continuous IV drip, maintanence IV fluids and oral Keppra. She was brought home sunday (7)17/16) c ~ 830 m & has returned to her normal Self, eating / drinking / playing & has had no more seizure activity.

**Eproduct expiration date unknown at present because I had thrown out the items case. However, I have been an RN, 10+ years a Know it was not expired. The company I purchased the Seresto solver from is trying to obtain the expiration date for me at present. I will submit follow up documentation if additional information is acquired.

FORM FDA 1932a (10/13)

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Center for Veterinary Medicine

Form Approved: OMB No. 0910-0645 Expiration Date: 4/30/2016 (See mailer page for Burden Statement)

VETERINARY ADVERSE DRUG REACTION, LACK OF EFFECTIVENESS, OR PRODUCT DEFECT REPORT (For VOLUNTARY Reporting)

NOTE: This report is authorized by 21 U.S.C 352 (a) and (f). While you are not required to report, your cooperation is needed to assure comprehensive and timely assessment of product labeling.

Individual Case Safety Report Number (FDA Assigned Number) | Submission Type

,	☑ Initial ☐ Follow-up	,
Report Type Adverse Event Product Problem	n Both Adverse Event and Product Problem	***************************************
Date of this Report (mm/dd/yyyy)	Date of Initial Report (If this report is a follow-up) (mm/dd/	
Month 1 Day 5 Year 2016	Month Day Year	
	Information	
First Name Katya	Last Name Hernandez	,
1503 Noble Forest Drive	·	
Novovoss State or F	Province Postal/ZIP Code SA 3097	
Country USA Telephon	e Number (Other) 865 1317 Telephone Number (Other)	
Fax Number Email Add	bella 18@gmaïl.com	
Sender Category Veterinanan Animal Ow Other Health Care Professional		
Sender Previously Reported to the Manufacturer?	(L'No	
If Yes, provide the Manufacturer's Case Number:		
No Identity Disclosure [Vi you do NOT want your	identity disclosed to the manufacturer, mark this box.	
Preferred Method of Contact Telephone Em	ail	
Health Care Professional Informa	tion (If different from Sender Information)	***************************************
First Name DY. Mary Port	Last Name H?!! RECEIVE	
Street Address 6225 Peuchtree Inclus	maj Blvd	## <u>#</u>
Atlanta	6A 30306	
Country USA Telephon	e Number O 455-101) Telephone Number (Other)	
Fax Number Email Add	dress	
FORM FDA 1932a (10/13)	Page 1 (N. Garaca Pari	nation El

18

	ation (If different from Ser	nder Information)
First Name	Last Name	
Street Address		
City	State or Province	Postal/ZIP Code
Country	Telephone Number	Telephone Number (Other)
Fax Number	Email Address	
Ser	<u> </u>	fiom
Activy - Spoton For Diagnosis and or Reason for Use of the Product I used Activy Las		atment.
Dosage Form (Chewable, liquid, tablet, topical, injecting of Chewable). Date of First Exposure (mm/dd/yyyy)	Date of Last E	xposure (mm/dd/yyyy)
Month 6 Day 26 Year 20 Duration of Product Use USed, PUSE 4 DUSE	XV	Month 6 Day 26 Year 2016
	e Information for Suspec	ted Product
Dose Administered L d05e Interval of Administration (Frequency) OWCE Route of Administration		
Product Administered By ☐ Veterinarian/Veterin	nary Staff D Owner	Other
Lot Number 50 410FO	i .	e (mm/dd/yyyy) DQH2 NO-1 1642 ON Month Day Year Paddeg
Name of Manufacturer of Suspected Product Merck Aprima I Heal H	•	

10746094

Form Approved: OM8 No. 0910-0645

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Center for Veterinary Medicine

VETERINARY ADVERSE DRUG REACTION, LACK OF EFFECTIVENESS, OR PRODUCT DEFECT REPORT

(For VOLUNTARY Reporting)

		CXDII	uuqi	ಬ್ರಾಣ	. 4100	720 m
(See	mailei	page	for B	urden	State	ment)
		<i>21,</i>				Parent C
						K. S
7						

				7/10/1	A.18100	MASS AN

NOTE: This report is authorized by 21 U.S.C 352 assure comprehensive and timely assessment of p	(a) and (f). W roduct labelir	hile you are not required to		peration is needed to		
Individual Case Safety Report Number (FDA Assigne	d Number)	Submission Type		7(
		<u> </u>	nitial	ollow-up		
Report Type 🔯 Adverse Event 🔲 Prod	luci Problem	Both Adverse Event and Product Problem				
Date of this Report (mm/dd/yyyy)	erene er	Date of Initial Report (If this	s report is a follow-	up) (m/n/dd/yyγy)		
Month 08 Day 02 Year 2016	6	Month	Day Yei	ar 🔝		
	Sender Ir	nformation				
First Name Kenneth		Last Name Tack				
Street Address 5102 Canyon Oaks Drive		(New cases)				
City Brighton	vince	Postal/ZIP Code 48114				
Country USA	Telephone N (810) 227-1		Telephone Numb	or (Other)		
Fax Number	Email Addre kjtack@com		<u> </u>	Annual Annual Annual Monte, del processor annual		
Sender Category Veterinarian	Animal Owne	(77) 151	57773			
Other Health Care Profess		er 🔀 Physician	∐ Patieni ∭ Unkno			
Sender Previously Reported to the Manufacturer?	Yes	⊠ No	***************************************	CTO		
lí Yes, provide the Manufecturer's Case Number:				AU6 1 8 2016		
No Identity Disclosure 🔀 If you do NO	f want your id	entity disclosed to the manu-	facturer, mark this i			
Preferred Method of Contact Telephone	(X) Email					
Health Care Professiona	l Informatio	on (if different from Send	der Information)			
First Name		Last Name				
Street Address		<u> </u>				
City	State or Pro-	vince	Postal/ZIP Code			
Country	Telephone ?	lumber	Telephone Numbe	er (Other)		
Fax Number	Email Addre	\$\$	<u> </u>			
FORM FDA 1932a (10/13)	Pag	je 1	**************************************	promounding and the		

			<u> </u>	4
Own. First Name	er Information (II di	fferent from Se	ander Information)	
La or waute		Last Name		***************************************
Paris Roomss				
City	State or I	Province	10	
		· ····································	Postal/ZIP Code	
Country	Telephor	ie Number	Telephane Number (Other)	1
			vergalant realities (Option)	:
ex Number	Email Adı	dress		
		······································		
	Suspected Pr	oduct Informa	atiom	***************************************
Jame of Suspected Product (cresto cellar (imidacloprid/flumethrin)				
Diagnosis and/or Reason for Use of the P	Face all and			
rophylaxis of tick and flea infestation	TOGUCI	enter de la companya del companya de la companya del companya de la companya de l	TO THE STATE OF TH	,
osage Form (Chewable, liquid, tablet, top upical - dog collar	oical, injection, etc.)			
ate of First Exposure (mm/dd/yyyy)	***************************************	Date of Last 8	xposure (min/dd/yyyy)	
Month 06 Day 6	Year 2016		Month 07 Day 21 Year 2016	
uration of Product Use				
pproximately 6 weeks				
Pro	duct line informati		2 190	**************************************
se Administered	duct Use Informatio	on for Suspec	tted Product	
ng collar				
erval of Administration (Frequency)	***************************************	****		
intinuous				
ule of Administration	**************************************			
g collar				
oduct Administered By				did No shiringan yang ang kanasa
(Veterinaria	an/Veterinary Staff	○ Owner	Other	
Number		Expiration Date	a (mm/dd/yyyy)	**************
known			<u> </u>	
ma of Magnifoctory - I C			Month Day Year	
me of Manufacturer of Suspected Produc	ž t			managan calendara.
ONG ED & 4020- (40/40)		***************************************		***************************************
mer nw 12979 (1813)	Pag	ge 2		17
RM FDA 1932a (10/13)	Pa	go 2		1/

	~^^~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	**************************************	9999996-30869999 day aday angeria				7	2740	694 —
			Adve	rse Eve	ent Infor	mation	*************		
Veterinarian's Leve	el of Suspic	ion that Produ							
		High	□м	edium		Low	⊠ Unknov	VI}	
Treatment of Adve Removal of collar	rse Event (Describe brief	ly)	and an annual section of the section	*************************				· .
Old Adverse Event	Abate Afte	r Stopping the			Did Advers	e Event	Reappear After Re		
Outcome	⊠ Rec	***************************************	Died		[] +62		□ No	[X] NO	I Applicable
	Walter		Species	***************************************	elated In	formati	An .	~~~	
Budgeriga	······································	Cat			***************************************				
Z Dog		Ferrel		C			Cockatiel		Cockateo
Horse		Human		******			Goat	j	Guinea Pig
☐ Sheep		Other (S	ресі(у)	Pan	TO!		Pig		Rabbit
Breed West Highland Ter	rier		,		0.00 (discussion)	Gender	Male Male Neu	-	Female Female Neutere
Age: 7 years					Weight:	20 lbs		Miles y very exchicum management to	· · · · · · · · · · · · · · · · · · ·
		Overall	Health Stat	us Whe	n Suspo	cted P	roduct Given	***************************************	
		Poor	☐ Poor ☐ Critical		Number of Animals Treated: 1				
***************************************	***************************************	60000000000000000000000000000000000000	**************************************			Nur	nber of Animals Al	lected. I	····
Charles To Control of the Control of		·		rse Eve	nt Occu	rrence			
Date of Ons et of Ac	iverse Eve	it (mm/dd/yyy)	y) Monti	n 07	Day 18	Year	2016		
Length of Time Bet Suspected Product Approximately 6 w	(s) and On:	Exposure to set of Adverse	Event	a ta			Between Last Admi ict(s) and Onset of		
When the Adverse	Event Occi	irred, Treatme	nt with Suspe	cled Pro	duci				
Had already b	een comple	eled	⊠ Was disc	ontinued] Was c	discontinued and re	placed wi	th another product
Was discontin	ued and re	introduced late	at.				continued at an afte		
Other (Specify	·)·	~ , ·					×	en voen	······································
			Doo	ument	Informa	tion		······································	
Attached Document	t Name (Fil	ename if Elect							
Attached Document	l Descriptio	n							
Attached Document	Name (File	aname if Electi	ronie)	~~~	······································	·			
Attached Document	Deșcriptio	ß			•••••••••••••••••••••••••••••••••••••••			***************************************	9
\ttached Document	Name (File	ename il Electi	ronic)		***************************************	······································	***************************************		
Attached Document	Description	3.					· · · · · · · · · · · · · · · · · · ·	*	
CAPALCON ASSOCIA	(A 5.7 & 5.1	XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX		>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>	00000000000000000000000000000000000000		00000000000000000000000000000000000000		
FORM FOA 1932a ((10/13)			Pag	ge 3				

	- Control of the Cont			674694
More There C	Con	current Clinical	Problem(s)	And the second s
Were There Concurrent Clinical Prob				7-1
1 (a) (b)	[] Yes	[∑] No	Do not know	☐ None
List Concurrent Clinical Problem(s)				
			9000000	
Concurrer	it Product Info	ormation (Exclu	ding Trealment of Curre	int Event)
ା ବ୍ୟର ନାର୍ଥ ନିର୍ମ୍ଦିୟ ପଦ name(s), dose(s) in	ferval(s) data(e)	afteastmanker .	mak military and a second second	**
The property of the limit opies of this form) or provide common the common provide common this form.	ro vi ium avani i	THE SECOND THE CO	CHOIC TO BECKER AND	fill out this section in other
Nere Concurrent Products Given?	senta m me ioni	marrative section	that follows this one	
The state of the s	Yes	67 kg	proms	····
list Names of Concurrent Products-A		⊠ No	Do not know	None
hat washan an entire it to the transfer with	iministered.	للتشريخ ويروا المرف يمح فقيدت ومعمودة ماه	the man activity to the grantes of a color and a color	ACAPT Address the String of the Section of the Sect
				,
abi of Cook C				
ate of First Exposure (mm/dd/yyyy)		Date	of Last Exposure (mm/dd/y	ууу)
Month Day	Year		Month Da	y Year
uration of Product Use			L	, , , , , , , , , , , , , , , , , , ,

	Adverse Even	VProduct Probl	em (Long Narrative)	
escribe the Adverse Event/Product P	roblem.			
he patient, a 7-year old male Wes	t Highland Ten	rier, was in excel	ent heath. On about June	6. a Scresto collar was
an each for bire sention of Helbittest H	uzstauon, (m. j.	uly 18 he became	lethargic and would not	eat. There was no known
change or courses of Sick Williams	JE HUHHANS,		· ·	
eterinary evaluation on July 21sh	owed a slight le	ver. Laboratory	testing at that time show	ed an ALT of 1335 ti/f.
ASSESS 443157 ANTOMORPH (47.17.17.17.17.17.17.17.17.17.17.17.17.17	ыны акяппет	Punchuaiaco 1774	\$ \$ \$77 \ \Columbia \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	1
lirubin. CBC showed total WBC	10 v 10 0.100 10 v 10 0 10 1	CL WED HORMSIN	eutrophils but lymphocy	tes were 12.8 x 10^6/mcL
JLN 5.1 x 10°6/mcl), monocytes cl.). Hemoglobin was normal. Th	e Seresia callar	was more as	ormeta), and platefets 87	x 106/mcL (LLN) 148 x 10°
n July 22, an abdominal ultrasour	id examination.	showed a normal	anneuring liver studies i	n the nott block to and a
and any and the presence that the state of t	∪. Gone ai a an	liereni laboratory	charged lemantage took	LA S. A. TONG Comment of the St. S. S. S.
. A MARCH DISCOURTER WESTERS WE	IS 200 - 430 X I	Unb/mcl with al	HOURS TOTAL WIRE DESIGN	while management and
mospoon were invitial, actology	for leptospiros	is was consistent	with previous vaccinatio	n. A diagnosis of
Argustonchannes was coustacted.				
n July 23, the dog's appealte and e	nergy were mus	ch improved. Or	al amoxicillin was started	d. Over the next few days, th
- A CONTRACT CONTRACT TO HOLIS	411.			
se patient's clinical course is cons	istent with a tox	tic hepatitis poter	itially caused by imidacle	prid/flumeth.in.
				ند.
2755 FM 3 3000 14000		**************************************	**************************************	
RM FDA 1932a (10/13)		Dagad		

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Center for Veterinary Medicine

VETERINARY ADVERSE DRUG REACTION, LACK OF EFFECTIVENESS, OR PRODUCT DEFECT REPORT

(For VOLUNTARY Reporting)

rom Approved: UMB No. 0910-0645
Expiration Date: 4/30/2016
(See mailer page for Burden Statement)

Individual Case Safe	ety Report Number (FDA Assign	ed Number)	Submission Type	
				Initial
Report Type	Adverse Event Pro	duct Problem	☐ Both Adverse Er	vent and Product Problem
Date of this Report	(mm/dd/yyyy)		Date of Initial Report (If th	is report is a follow-up) (mm/dd/yyyy)
Mont	n 10 Day 22 Year 20	15	Month	Day Year
		Sender Ir	formation	
First Name Jane			Last Name Lucy	
Street Address 14508 Broadway Ro	oad	***************************************	<u> </u>	
City		State or Pro	vince	Postal/ZIP Code
Onancock		VA		23417
Country United States		Telephone 1 757-787-27		Telephone Number (Other) 757-768-7828
Fax Number		Email Addre	88	
Sender Category			F****	Print
	38000	Animal Owne		∐ Patient
	Other Health Care Profes	sional	Other	Unknown
Sender Previously	Reported to the Manufacturer	? Yes	☐ No	
f Yes, provide the M	lanufacturer's Case Number			
lo Identity Disclos	ure 🔲 If you do NC	T want your ide	entity disclosed to the manu	ufacturer, mark this box.
Preferred Method o	·	☐ Email		
**************************************	Health Care Profession	al Informatio	on (If different from Sen	der Information)
First Name	WWW.datasassassy.	•••••••••••••••••••••••••••••••••••••••	Last Name	
)rew			Humphries	
Street Address Eastern Shore Anim	al Hospital, 34424 Lankford Hig	hway		
lity 'ainter		State or Prov	vince	Postal/ZIP Code 23420
Country Inited States		Telephone N 757-442-315		Telephone Number (Otner)
ax Number		Email Addre	\$5	1
ORM FDA 1932a (*	(A)34)			FSC Engines (301) 413-10781

Owner Informa	ation (If differen	t from Sender I	Information)
First Name	Lä	st Name	
Street Address			
City	State or Provinc	æ	Postal/ZIP Code
Country	Telephone Nun	ber	Telephone Number (Other)
Fax Number	Email Address		
Sus	pected Produc	t Informatiom	
Name of Suspected Product Scresto Flea Collar	\$		······································
Diagnosis and/or Reason for Use of the Product Was prescribed by Veterinarian to help control fleas.			***************************************
Dosage Form (Chewable, liquid, tablet, topical, inject Flea Collar	ion, etc.)		
Date of First Exposure (mm/dd/yyyy)	Di	ite of Last Exposi	ure (mm/dd/yyyy)
Month 10 Day 10 Year 201	15	Mon	th 10 Day 15 Year 2015
Duration of Product Use 5 days	*****		
Product Use	e Information f	or Suspected	Product
Dose Administered N/A Flea Collar			
Interval of Administration (Frequency)			
·			
Route of Administration			
Product Administered By		·····	· · · · · · · · · · · · · · · · · · ·
Veterinarian/Veterin	nary Staff	∑ Owner	Other
Lot Number	[E	piration Date (mr	n/dd/yyyy)
		Mon	th Day Year
Name of Manufacturer of Suspected Product			
Bayer HealthCore LLC	AN [®] AND THE BARBARY THE STREET ST		
FORM FDA 1932a (10/13)	Page	2	

		***************************************				***************************************	***************************************	***************************************
	***************************************			vent Infor	mation	***************************************		
Veterinarian's Level	•							
	☐ Hig		Medium		Low	⊠ Un	known	
Treatment of Adver- Patient presented w			ng. Patient	was treated	for diarrhe	and vomit	ing.	
Did Adverse Event	Abate After Stoppin	g the Product	?	Did Advers	e Event Re	eappear Affe	er Reintrodu	ction of the Product?
☐ Yes	⊠ No	☐ Not App	licable	☐ Yes		□ No	\boxtimes	Not Applicable
Outcome	Recovered	⊠ Died	[] Othe	i.				
		Spec	cies and l	Related In	formatio	n		
☐ Budgerigar	[汉] Gai			attle		Cockatie		Cockatoo
☐ Dog	☐ Ferret ☐ Fis		ish		Goat		Guinea Pig	
☐ Horse	☐ Hui	man	P	arrot] Pig		Rabbit
Sheep	□ O#	ier (Spacify): _						
Breed	*************************************				Gender	X Male		T Female
Persian							Neutered	Female Neutered
Age: I year 6 month	18	tanta and a second		Weight:	10 lbs 8 o	Z.		
	Ove	rall Health	Status W	hen Suso	ected Pro	duct Giv	en	***************************************
····						er of Anima		·····
	⊠ Good □	Fair	Poor [Critical	-		ils Affected:	
***************************************		***************************************	Academic Par				ADMINISTRA SERVICE SER	***************************************
Date of Onset of Ad	verse Event (mm/d	ld/vvvv)		vent Occu	***			
			Month 10	Day 13	Year	2015		
Length of Time Bety Suspected Product(3 days							Administrati set of Adver	
When the Adverse B	vent Occurred, Tre	eatment with S	uspected F	l 'roduct			 ,	***************************************
Had already be	en completed	☐ Was	discontinu	ed [] Was dis	continued a	and replaced	I with another product
Was discontinu	ed and reintroduce	ad later		[☐ Was co	ntinued at a	n altered do	se
	Patient was treat	ed for nausea a	md vomitir	g, the next o	lay, the col	lar was rem	oved as not	hing was working.
bhiteiniann respective and a second s	delininimuusuusissidudisisidelikkiisidelininmuusuusuusuusuusuusuusuusuusuusuusuusuus		Docume	nt Informa	etion	**************************************	~~~~~	···········
Attached Document	Name (Filename it	Electronic)		***************************************	~ ******	······································		
Letter of complaint	/ concerns with det	tails to Bayer I	-lealthCare	LLC				
Altached Document	Description			-		***************************************	***************************************	
Attached Document	Nam e (Filename il	Electronic)	·	dacacacacacacacacacacacacacacacacacacac	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		······································	
Attached Document	Description		AAAAA AAAAA AAAAA AAAAA AAAAA AAAAA AAAA	haan an	***************************************		***************************************	
Attached Document	Name (Filename il	(Electronic)	· · · · · · · · · · · · · · · · · · ·		······································			
Attached Document	Description		······································					
CODE ENA 4000- 4	40142\		Voncennonconnecon	Oana?	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		000000000000000000000000000000000000000	concentrations. Joseph Section and Sections
FORM FDA 1932a ((VI 19)			Page 3				

Were There Concurrent Clinical Problems? Yes	other products
List Concurrent Clinical Problem(s). Patient had soft stools, treated for RoundWorms with ProFender. Concurrent Product Information (Excluding Treatment of Current Event) Please provide name(s), dose(s), interval(s), date(s) of treatment(s), and other relevant information to describe that the patient was taking at the time of the event. Either copy this section as needed (you may fill out this sect copies of this form) or provide comments in the long narrative section that follows this one. Were Concurrent Products Given? Yes No Do not know None List Names of Concurrent Products Administered. ProFender Cerenia Albon SubQ Fluids Vitamin B12 Injection Date of First Exposure (mm/dd/yyyy) Month 10 Day 10 Year 2015 Month 10 Day 13 Year	other products
Patient had soft stools, treated for RoundWorms with ProFender. Concurrent Product Information (Excluding Treatment of Current Event) Please provide name(s), dose(s), interval(s), date(s) of treatment(s), and other relevant information to describe that the patient was taking at the time of the event. Either copy this section as needed (you may fill out this sect copies of this form) or provide comments in the long narrative section that follows this one. Were Concurrent Products Given? Yes No Do not know None List Names of Concurrent Products Administered. ProFender Cerenia Albon SubQ Fluids Vitamin B12 Injection Date of First Exposure (mm/dd/yyyy) Month 10 Day 10 Year 2015 Month 10 Day 13 Year	other products
Concurrent Product Information (Excluding Treatment of Current Event) Please provide name(s), dose(s), interval(s), date(s) of treatment(s), and other relevant information to describe that the patient was taking at the time of the event. Either copy this section as needed (you may fill out this sect copies of this form) or provide comments in the long narrative section that follows this one. Were Concurrent Products Given? Yes	other products tion in other
Please provide name(s), dose(s), interval(s), date(s) of treatment(s), and other relevant information to describe that the patient was taking at the time of the event. Either copy this section as needed (you may fill out this sect copies of this form) or provide comments in the long narrative section that follows this one. Were Concurrent Products Given? Yes	other products tion in other
Please provide name(s), dose(s), interval(s), date(s) of treatment(s), and other relevant information to describe that the patient was taking at the time of the event. Either copy this section as needed (you may fill out this sect copies of this form) or provide comments in the long narrative section that follows this one. Were Concurrent Products Given? Yes	other products tion in other
Please provide name(s), dose(s), interval(s), date(s) of treatment(s), and other relevant information to describe that the patient was taking at the time of the event. Either copy this section as needed (you may fill out this sect copies of this form) or provide comments in the long narrative section that follows this one. Were Concurrent Products Given? Yes	other products
Please provide name(s), dose(s), interval(s), date(s) of treatment(s), and other relevant information to describe that the patient was taking at the time of the event. Either copy this section as needed (you may fill out this sect copies of this form) or provide comments in the long narrative section that follows this one. Were Concurrent Products Given? Yes	other products
Please provide name(s), dose(s), interval(s), date(s) of treatment(s), and other relevant information to describe that the patient was taking at the time of the event. Either copy this section as needed (you may fill out this sect copies of this form) or provide comments in the long narrative section that follows this one. Were Concurrent Products Given? Yes	other products tion in other
that the patient was taking at the time of the event. Either copy this section as needed (you may fill out this sect copies of this form) or provide comments in the long narrative section that follows this one. Were Concurrent Products Given? Yes	other products tion in other
copies of this form) or provide comments in the long narrative section that follows this one. Were Concurrent Products Given? Yes	tion in other
Were Concurrent Products Given? Yes	
✓ Yes No Do not know None List Names of Concurrent Products Administered. ProFender Corenia Albon SubQ Fluids Vitamin B12 Injection Date of First Exposure (mm/dd/yyyy) Month 10 Day 10 Year 2015 Month 10 Day 13 Year	
List Names of Concurrent Products Administered. ProFender Cerenia Albon SubQ Fluids Vitamin B12 Injection Date of First Exposure (mm/dd/yyyy) Month 10 Day 10 Year 2015 Month 10 Day 13 Year	
ProFender Cerenia Albon SubQ Fluids Vitamin B12 Injection Date of First Exposure (mm/dd/yyyy) Month 10 Day 10 Year 2015 Month 10 Day 13 Year	
Cerenia Albon SubQ Fluids Vitamin B12 Injection Date of First Exposure (mm/dd/yyyy) Month 10 Day 10 Year 2015 Month 10 Day 13 Year	and the same of th
Albon SubQ Fluids Vitamin B12 Injection Date of First Exposure (mm/dd/yyyy) Month 10 Day 10 Year 2015 Month 10 Day 13 Year	
SubQ Fluids Vitamin B12 Injection Date of First Exposure (mm/dd/yyyy) Month 10 Day 10 Year 2015 Month 10 Day 13 Year	
Vitamin B12 Injection Date of First Exposure (mm/dd/yyyy) Month 10 Day 10 Year 2015 Month 10 Day 13 Year	
Date of First Exposure (mm/dd/yyyy) Month 10 Day 10 Year 2015 Date of Last Exposure (mm/dd/yyyy) Month 10 Day 13 Year	
Month 10 Day 10 Year 2015 Month 10 Day 13 Year	
Duration of Product Use	2015
Adverse Event/Product Problem (Long Narrative)	2000-2000-200-200-200-200-200-200-200-2
Describe the Adverse Event/Product Problem.	
As per the advice of our Veterinarian, I placed the flea collar on my cat on Saturday, October 10. On Tues	sday October
13, I noticed a small amount of diarrhea, and on Wednesday, October 14, I discovered where he had vomi	•
night. I tried to syringe a little water for him, but he foamed/drooted excessively. I immediately took him	
told him that Nuggett showed all the signs of being poisoned, but I could not explain why, as there was no	
	**
have gotten into. Our Vet assured me that the collar was safe, and left it on. The next day, Nuggett was s	
and I insisted we remove the collar. During this time, Nuggett was also administered ProFender (also man	

Bayer HealthCare LLC). The Veterinarian agreed that Nuggett was having an adverse reaction/poisonous reaction to the product (s). The following morning, Nuggett threw up blood, crashed and passed. Prior to all of this, he had been a thriving, healthy, growing one year old. It should be noted that on Wednesday, October 14, the choice to leave Nuggett at the vet was mine so that the Vet could obtain a stool sample. All blood work came back showing a perfectly healthy cat. Please see attached letter for explicit details of the events and treatments.

File a Report

Patricia J. Johnson 710 Beech St. Rome, New York 13440 Raceived



This form provides a way for you to collect the information you will need to submit when you are ready to submit this form online. We encourage you to use the online form to formally submit a report. However, if you can't fill in the online form, you may choose to print this form and mail a signed copy to the address on the right. Do not send in the form and fill it out online, only submit it once.

If you are unsure about how to fill in a multiple-selection field in this form skip it. Please make sure that you provide full detail in the description of the hazardous incident or safety concern.

US Consumer Product Safety Commission 4330 East West Highway Bethesda, MD 20814 Attention: Safety Complaint

> Phone: 1-800-638-2772 E-mail: info@cpsc.gov www.saferproducts.gov

* Indicates required field * I am a / I em-affiliated with: **N**Consumer Local Government Agency State Government Agency Federal Government Agency Public Safety Entity Health Care Professional Medical Examiner and Coroner Child Service Provider Tell Us What Happened * I am reporting: A hazardous incident: An actual incident or injury involving an unsafe consumer product. A safety concern: The potential for an unsafe consumer product to cause an incident or injury. *Please describe the hazardous incident or safety concern: Serious. Important: Include details such as how the product was being used, what happened to prompt your report and

Disclaimer: The Commission does not guarantee the accuracy, completeness or adequacy of the contents of the Consumer Product Safety information Database, particularly with respect to the accuracy, completeness or adequacy of information submitted by persons outside of the CPSC.

ony injuries that were sustained. Do not provide personally identifiable information in this box.

Tell Us What Hap	pened (continued)
*incident Date: (mm/dd/yyyy)	9-5 Thu 10-22 Is this an Estimated Date? ☐Yes XNo
Location:	
MHome Apar	tment / Condominium
1 / warmen	nufactured Home
	eation or Sports
Street or High	*
☐School	····ay
Industrial	
Farm / Ranch	3
-	Property /Office
Unknown	, , ,
	<u> </u>
Incident Address:	Tio Beech St.
Apt / Office / Suite:	
City:	Nome
State:	
Postal Code:	13440-2214
Country:	LUSA
This is my home	e address
People involved a	nd Their Injuries
This section only app	olies if you are reporting a hozardous incident, not a safety concern.
For each victim invol	ved you will need to provide the following information. We have provided space for one in the online report you can enter the information for many victims.
Number of Victims Involved	The term "victim" covers any individual killed, injured or exposed to a possible product-related hazard and does not imply that the product caused an incident.
* Injury Information	(select ane):
Incident, No	
	rst Aid or Medical Attention Received
☐Injury, First A	4
∏Injury, Medic	cal Attention Received
	gency Department Treatment Received
Injury, Hospi	tal Admission
Death	

Patricia J. Johnson 710 Beech St. Rome, New York 13440

Location of Injury (if applicable):						
25 - 50 % of body Foot		Neck				
All parts of body (more than 50% of b	ody)	Pubic Region				
Ankie		Shoulder (including clavicle, collarbone)				
Arm		Toe				
∏Ear ⊠intern	I (use with Aspiration and Ingestion					
□Elbow □Knee	the transfer and account and substitute					
Trunkall		Wrist				
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐	ered	Not Recorded				
Finger Mouth	•					
Type of Injury (select up to two):						
Amputation Disloc		ct Swallowed				
☐ Bleeding ☐ Drown		_				
§ mms	c Shock Punc	ture				
yapang	n Object Stuck in or On the Body					
, , , , , , , , , , , , , , , , , , ,		re Bruising				
Concussion Lack o	f Oxygen Skin	Tear, Skin Flap, Nail Detachment				
☐Cut ☐Nerve	Damage Strai	n, Sprain				
Dental injury Object	Inhaled Othe	r/Not Stated				
Dermatitis, Conjunctivitis, Skin or Eye						
Your relationship to this victim:						
Self						
☐My child	Other relative					
-	☐My friend /neighbor / co-w					
∭My parent		etç. (professional relationship)				
☐Mγ spouse	No relationship					
Victim's Gender: Male	X Female アルム	- 424				
Victim's age at the time of the incident:	[,				
For children under age 3, provide the age	in years and months	rs /0 Months				
Victim is of Hispanic/Latino origin	******					
THIN THE PARTY OF	c3 (1),40					
Victim's Race: White	Other					
☐Black/African American	-	· · · · · · · · · · · · · · · · · · ·				
Asian Specify Other Race:						
American Indian/Alaska Native						
Native Hawaiian/Pacific Is	lander					
Unknown						
Victim's First Name:						
vicum's rirst name:	E-mail					
Víctim's Last Name:	Phone	200000000000000000000000000000000000000				
£	TOTAL	•				
☐The victim's address is the ☐Use the address below.	same as the incident address.					
Victim's Address:	Ao	t / Office / Suite:				
City:		istal Code:				
Country:						
	J					

Tell Us About the Product							
In order to investigate your report, CPS	C needs to know about the product. P	roduct identification found bit					
labels or manuals is especially importar	it. We ask that you hil in as much imo	Higher as And can engar our					
product. **Product Category (select one):	4						
	Hobby	Sports & Recreation					
Clothing & Accessories	Mome Maintenance & Structures	Toys, Kids, & Baby					
Containers & Packaging	Kitchen	☐Yard & Garden					
☐Drywall· ☐Electronics	Personal Care	None of these					
Fuel, Lighters & Fireworks	Products at Public Facilities						
	Furniture, Furnishings & Decorations						
. D-ad-ect Description							
Important: Please write a description	of the product, including the product	name and any other information					
m dere de la constante de la c	and novemore for which it is used	· · · · · · · · · · · · · · · · · · ·					
Frijer Sexes to Flea & 1.	it Collar of Small I	2094 Company to					
In I mouledged by kind adverse share of Fects from the polison							
Bayer Seresto Flewa 17th Collar for Small Dogs. Company that a Knowledged Dog that adverse side of fects from the polision is are willing to Day 321.83 of the \$1591.79 Vet Bills plus is are willing to Day 321.83 of the \$1590.79 Vet Bills plus							
	IF I MVC I CI WAR	2 Has payment us					
#65.24 Bathe collar I have refused this payment as well as the original amount of \$ 130.17.							
well as the original amount of or 120.							
	Tea Trick Collar F	La Van III Dace					
Brand Name: Seresto F							
Model Name or Number:	Serial Number: 4	Lot# AHNSOLYT					
835300 3453350 50 7453360		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					
Manufacturer/Private Labeler Name:	Bayer Healthcare, LLC	! Animal Health DIVISION					
Date Manufactured (mm/dd/yyyy):							
Date to see the see of		5/2/3					
Manufactured Date Code:	V-01/2015 (84586560)						
Manufacturer or Private Labeler	PO Boy 390	390					
Address: (if known)							
Purchased From (Store	Retailer Loca	ation (State): New YOFK					
Purchased From (Store Name or Internet site): Nactor Supply Retailer Location (State): New York							
Purchase Date: //	07-20/6 Is this an I	Estimated Date? ☐Yes					
(mm/dd/yyyy)							
More Important Questions About the Product							
Listill have the product.							
(Please try to keep the product for at least 30 days after submitting the report for CPSC's use.)							
The product was damaged before th	, mund						
The product was repaired before the		o [X]N/A					
The product was modified before th		o [X]N/A					
·	terror terror	**************************************					
Have you contacted the manufactur	Carrier Carrier						
1) ((4), 20) (4)							
NOTE: The online form contains a section where you may upload pictures or similar documentation from your computer. You are encouraged to submit pictures of the product, its packaging, bar code or other identifying information.							

Patricia J. Johnson 710 Beech St. Rome, New York 13440

1.001.001110000 111100111				
Please provide you co Public Database.	ntact information below. You	r name and conta	ct information will nev	er appear in the
*First Name: Pata	e1011 - J	Last Name:	JOHNSON	7
You must be 18 years of contact information fo	old to submit a report. If you a r your parent or guardian. CP	are not 18, please SC will contact thi	skip down the form ar	nd provide the
🛛 I am 18 years of ag			,,	, - 1 1 1 1 1 1 1 1 1 1
	Ay contact address is the same ise the address below.	e as the incident :	address.	
*Address:			Apt / Office / Suite:	200000000000000000000000000000000000000
*City:		*State:	*Postal Code:	
Country:	**************************************	***************************************		
E-mail: VEW77	QVENTURE@AOL.CO	The Phone:	315-337-	1846
Please provide a parei	nt or guardian's information	below only if you	are younger than 18 y	/ears old.
First Name:		Last Name:		
Phone:		E-mail:		
Address:		***************************************	Apt / Office / Suite:	
City:		State:	Postal Code:	
Country:				
Consent & Submit		······		
	you would like us to handle		**************************************	***************************************
dMay we include your re without your name an	eport including any document d contact information, in CPS	is or photographs IC's Public Databa	that you have attache	d to your report, but
	clude my report in the Public		321	
`_No, do not inclu	ide my report in the Public Da	itabase.		
May we release your na	ame and contact information	to the product m	anufacturer or private	labeler?
∠z₁ res, you may re □No, do not relea	lease my name and contact in ase my name and contact info	nformation to the ermation to the pe	product manufacturer	or private labeler.
	and the same of the same of the same	monom to the pr	anacı mamarınızı Di	private labeler.
By signing this form I ce knowledge, information	ertify that the information pro n, and belief.	ovided in this repo	ort is true and accurate	to the best of my
1	1			,
Talesca 49	hasel		11-17-	16
Signature // /			Date	

Jane W Lucy 14508 Broadway Road Onancock, Virginia 23417

October 21, 2015

Bayer HealthCare LLC Animal Health Division P.O. Box 390 Shawnee Mission, Kansas 66201

To Whom It May Concern:

On Saturday, October 10, we put a Seresto Cat Collar, manufactured and distributed by your company, on our one year old Flame Point Persian, Nuggett. Nuggett was a virile, healthy, perfect little cat who had thrived in his first year with us. The Seresto Collar was strongly recommended by our Veterinarian. I have never been a fan of using flea collars on cats, however, considering that we live in a very low, damp area, and consequently, even though our cats are never, ever allowed outside, fleas still become a problem. And so, despite my concerns, we trusted our vet and purchased not only one, but four collars for all of our fur-children. Our vet also put him on Metronidazole for soft stools.

The next several days, Nuggett presented no symptoms, but then, on Tuesday, October 13, Nuggett had a small amount of very liquid diarrhea. By Wednesday morning, October 14, he had also thrown up several times and would drool/foam excessively when I would attempt to syringe water in him to make sure he was hydrated before leaving home to take him to our vet. Nuggett presented all the symptoms of having been poisoned; there was no fever, and his health was otherwise perfect according to all tests run. They found evidence of roundworms, so he was treated with Profender. The vet could not find anything that would explain what was happening, and so I asked that he be allowed to stay with them until he had another bowel movement so they could test to see what was going on.

By that night, Nuggett still had not had a bowel movement, so we decided to let him stay overnight. On Thursday morning, October 15, I called our vet and Nuggett had more vomiting and a little more diarrhea. The vet said his heart and lungs were strong, and the blood work had come back great, with absolutely no cause for concern. There simply was no explanation for what was going on. When I went to visit with him that day, he was a little quiet, but did not seem to be in any distress, and was happy as I sat in the floor loving him, even trying to escape his kennel as I stood up to speak with the vet when he came in. The vet stated he had tightened the Seresto Collar as he still saw a few live fleas. As we sat there talking, trying to figure out what, if anything he could have possibly gotten into that would have caused this, we ruled out each and every possibility; we are extremely conscientious pet owners, there wasn't/isn't a single thing in our house that would be dangerous to them, nothing. I asked the vet to remove the collar immediately, it was the only thing that could possibly be causing this type of problem.

Friday morning, October 16, I called to speak with the vet, and the report was unchanged. Nuggett was strong good heartbeat, lungs strong and clear, but still having diarrhea, this time, bloody. They had tested his stool and found coccidia, and had treated him with Albon, and he had tolerated the medicine and not thrown it up. We discussed my concern that Nuggett wasn't eating or drinking, and the vet stated he would attempt to syringe feed him a little that morning, and administer Sub Q fluids to ensure hydration. He suggested I Lring some of his food from home that may be more appealing to him and help coax him to eat. Less than 30 minutes later, the vet called and informed me that Nuggett had vomited, this time bloody vomit, and was crashing. My beautiful, healthy, vibrant little boy could not breathe on his own and his heartbeat was fading.



Jane W Lucy 14508 Broadway Road Onancock, Virginia 23417

October 21, 2015

Center for Veterinary Medicine Food and Drug Administration 7519 Standish Place, HFV-1 Rockville, MD 20855

To Whom It May Concern:

Attached please find FDA Complaint Form 1932a along with a copy of my letter of complaint/concerns which I have sent to Bayer HealthCare LLC. I appreciate any help and attention you may be able to offer.

Thanking you in advance.

One wohing

Sincerely,

Jane W Lucy 14508 Broadway Road Onancock, VA 23417 757-787-2705

enc.

We raced to the veterinary office where our vet and his staff were working fervently over Nuggett to keep him alive until we got there. But it was too late, if they stopped massaging his little heart, it simply would not beat on its own. So we were left to accept the fact his little heart wasn't beating, his little lungs weren't breathing ... we were left to say goodbye to our beautiful, strong, healthy little one year old baby, a baby that should have had fifteen or more years of a pampered, privileged life to enjoy.

I have several areas of concern here. As a short recap, to begin with, prior to Saturday, Nuggett was healthy, growing, active, very, very much a normal healthy cat. Because his stools were a little soft, and because we had begun to see a few fleas, we took him to the vet. Our vet records will show that all of our babies get the very best veterinary care possible, we always err on the side of caution, taking them in just to be safe if a problem or issue presents itself, so their health was always our utmost concern, hence the trip to the vet on Saturday. The vet told us to put the Seresto collar on him, and treated him with Metronidazole for soft stools. A little less than a year ago, Nuggett had taken Metronidazole when we had changed his food and his stools had become soft. There were absolutely no ill effects from the medication, and no cause to believe this affected him adversely at this time either, since he had taken it before without incident. Saturday, Sunday and Monday, Nuggett continued to be a completely healthy, virile cat, Playful, good appetite, eating and drinking normally, no signs whatsoever of anything wrong. Then, Tuesday night, the diarrhea. On Wednesday morning, I awoke to discover that he had yomited, and we called the vet, telling them we were bringing him down. Before leaving I syringed a little water into his mouth, upon which he started drooling and foaming profusely. Please keep in mind that at this point, Nuggett was still active, rushing into whatever room we walked into, outside of the diarrhea and vomiting, there were absolutely no signs of debilitation. Once we arrived at the vet, they treated him with Profender. They tightened his Seresto collar the next morning as they still saw a few live fleas. He was treated with Cerenia for the nausea and vomiting, which had no effect, as he continued to have a few episodes of vomiting. I asked our vet to remove the collar and he did. When I returned home, we had agreed that we would both do some research into possible side effects of the collar, and so I began searching for potential problems. I was not happy at all with the complaints and problems I was finding, many horrific stories of consequences and death to pets that had been subjected to the Seresto collar, and so I immediately called our yet and told him under no circumstances was he to put that collar back on my baby.

Since Nuggett left us on Friday, our family has been grieving in a way we did not know was possible. This beautiful healthy cat was dead, for no reason, no explanation, no justification. When I left him on Thursday evening, I certainly didn't in a million years, expect that I would never see him again. I do not know how to come to grips with this, I cannot wrap my head around the fact that he is gone. Why?

I told our vet when we left on Friday that I would be contacting your company to express my concerns over the role your Seresto collar has played in Nuggetts death. When I sat down to write you yesterday, I wanted to make sure that I had done all of my research before I began, and just imagine my surprise when I learned that the Profender, which was applied to Nuggett on Wednesday night, is also made by your company, and also carries horror stories of reactions from people that have suffered devastating consequences, even pet death, after using your product.

Yes, Nuggett presented with coccidia on Thursday, which in an extreme case, can cause death. However, as I am certain you are aware, a large percentage of cats carry the coccidia parasite in their bodies, where it lies dormant causing no symptoms or problems throughout their entire lives. It presents itself most frequently in young kittens, only rearing its heads in older cats who have a weakened immune system. I would like to remind you that Nuggett was a healthy, strong and growing cat prior to having the collar put on him on Saturday.

I do not know if the Seresto Collar is to blame for his quick decline, or perhaps the Profender application on Wednesday night. Realistically, it could have been a combination of the two, these very potent poisons coursing through his little body to further weaken and debilitate him. I do know that on Wednesday night, the vet was ready to send him home, it was my decision to leave him there so that they could get a stool sample, and I also know that it was only after the application of YOUR products that my precious, amazing little papy began his decline. At no point, let me repeat that, at NO POINT did any of us think for one minute my heautiful baby was on deaths door, prior to his demise Friday morning.

The bottom line is, your product or a combination of your two products caused Nuggett to crash, and subsequently pass. It is completely irresponsible and unethical that your company does not provide a warning

to pet owners of the possible dangers associated with these products. I don't care if it is only one cat out of all the many you tested; if there is an adverse reaction - ONE adverse reaction, pet owners need to be aware of that potential side effect. It is also heinously irresponsible for you to push these products as safe to use together, particularly on a cat that is having symptoms such as nausea and/or diarrhea; what possible good can come from putting all of these poisons into a tiny cats body when their system is already having another issue?

In your rush to promote these products you have affected so very many lives in such a horrific, tragic way. To begin, a beautiful, healthy, vigorous and spirited baby is gone, taken from us at only one year old, robbed of an amazing, wonderful life. We, his parents, are left reeling, a void that is both devastating and crushing consuming our every waking moment. Although yes, Nuggett was a beautiful purebred "animal" he was never JUST an animal to us, he was a member of our family, he was loved, he was cherished. Your products have stolen precious years with this beloved family member from us, and that is unforgivable. But there is more. Just for a moment, can you also think about our vet? Our vet recommended your products based on YOUR assurances, YOUR promises, YOUR statistics. Can you for just a moment think about how he feels, knowing that this amazing creature is gone because of what HE recommended? Our vet is one of the most loving, compassionate, skilled and competent vets I have ever had the pleasure to work with, I cannot Imagine the hell he is dealing with right now, all because he took your words in good faith. How dare you put any of us in this situation, leave us with this crippling grier? HOW DARE YOU?

Rest assured that we not only feel this issue needs to be resolved, but that we will not rest until Nuggett's death can stand for something. HE WILL NOT HAVE DIED IN VAIN ... every ounce of strength I have within me will be devoted to ensuring that you and your company right this wrong, and that this never, ever happens again to an unsuspecting pet parent.

Sincerely,

Jane W Lucy

14508 Broadway Road Onancock, VA 23417

757-787-2705

Veterinary Hospital: Eastern Shore Animal Hospital 34424 Lankford Highway

one way

Painter, VA 23420 757-442-3150

Attending Veterinarian: Dr. Drew Humphries

cc: Center for Veterinary Medicine, FDA



Cc: Milbourn, Cathy

Subject: Getting deadline --- WNBC-TV NY- consumer producer asking about Seresto dog collar

Hi Cathy,

Can you help us with a story we are working on?

We were contacted by a viewer about her experiences using a flea and tick dog collar called the Seresto dog collar and she claims that after using it for four months, her dog went blind as a result. I am pasting her original email to us below.

Do you have any complaints on file about it? any investigation? Anything you can share would be very much appreciated! Thank you,

Doreen WNBC-TV consumer producer 212-664-6252

FROM THE PET OWNER:

From: Sarah Ziolkowski [mailto:s.m.e.ziolkowski@gmail.com]

Sent: Sunday, June 28, 2015 7:40 AM

To: Consumer Help

Subject: Seresto dog collar

Last August my vet told us about a new dog collar made by Bayer- called Seresto- that was supposed to be safe and prevent fleas and ticks. I was pregnant at the time, and we hated using the drops because we have a cat and the drops are dangerous for cats. So we, like my parents, listened to our vet and got the Seresto collar. The vet fit the collar for my dog (a Cockapoo) and we were told we would need a new one in 8 months.

My dog started acting differently shortly thereafter. She began eating our cat's food (something she had never done in her ten years) and by December was completely blind. We equate this entirely with the Seresto dog collar as she had NO health issues before placement of this collar.

My parents had also used the Seresto collar on their miniature schnauzer, and he too experienced severe medical issues, which ultimately led to his death. He admittedly had some issues before using the collar, but after using the collar he experienced different issues which lad to my parents expending a fortune on his medical care. He was hospitalized for kidney failure and kept in ICU for several days. He was in and out of the pet hospital for weeks before my parents had to ultimately put him down.

Shorty after his death, my parents got two puppies. Despite my urging, my parents put the Seresto collar on the puppies (at their vet's recommendation) only to learn that the collar got caught on a piece of furniture, nearly choking one of them to death!

Finally, my best friend also had a negative experience with the use of the Seresto collar on her morkipoo. Her dog wore it only for a few hours and the negative effects were immediately known. The dog began to vomit and wouldn't eat. She became dehydrated and lethargic and also required hospitalization. She, luckily, removed the collar in time and has no long term negative effects from its use.

I have contacted Bayer and they said they would lodge a report with the FDA. However, i

-003

2

want other consumers to be aware of the dangers of this product. While i realize there could be other causes of all of the incidents I have reported above, the single common factor is the use of the Seresto collar.

I would welcome the opportunity to discuss further. Sarah M. Ziolkowski

Catherine C. Milbourn
U.S. EPA HQ
Office of the Administrator
Office of Media Relations
202-564-7849 (office)
202-420-8648 (mobile)
Milbourn.cathy@epa.gov

EXHIBIT D

Index to Exhibit D

(Petition to Cancel Registration of PNR1427 (Brand Name Seresto) under the Federal Insecticide, Fungicide, and Rodenticide Act; Reg. No. 11556-155)

- 1. EPA, Notice of Pesticide Registration, Reg. No. 11556-155 (2012), https://www3.epa.gov/pesticides/chem_search/ppls/011556-00155-20120316.pdf.
- EPA, Weighing Risks to Children from Dogs Wearing Seresto Collars (2016), https://www.epa.gov/sites/production/files/2017-01/documents/weighing-risks-to-children-from-dogs-wearing-seresto-tm-collars.pdf.
- 3. EPA, Preliminary Terrestrial Risk Assessment to Support the Registration Review of Imidacloprid, at 11-12 (2017), https://www.regulations.gov/document/EPA-HQ-OPP-2008-0844-1256.
- 4. Szymanski, J., et al., Rusty Patched Bumble Bee (Bombus affinis) Species Status Assessment (2016), https://ecos.fws.gov/ServCat/DownloadFile/120109.
- 5. Jennifer Hopwood, et al., The Xerces Soc'y for Invertebrate Conservation, *Are Neonicotinoids Killing Bees*?, at vi (2012), http://cues.cfans.umn.edu/old/pollinators/pdf-pesticides/Are-Neonicotinoids-Killing-Bees_Xerces-Society.pdf/.
- 6. Barraud, A., et al., *The Impact of Pollen Quality on the Sensitivity of Bumblebees to Pesticides*, 105 Acta Oecologica 103552 (2020).
- 7. Whitehorn, P. R., et al., Neonicotinoid Pesticide Reduces Bumble Bee Colony Growth and Queen Production, 336 Science 351–352 (2012).
- 8. Feltham, H., Park, K., Goulson, D., Field Realistic Doses of Pesticide Imidacloprid Reduce Bumblebee Pollen Foraging Efficiency, 23 Ecotoxicology 317–323 (2014).
- 9. Christoph Sandrock et.al., Sublethal Neonicotinoid Insecticide Exposure Reduces Solitary Bee Reproductive Success, 16 Agricultural & Forest Entomology 119 (2014), https://beyondpesticides.org/assets/media/documents/pollinators/documents/Sandrocketal 2013 Sublethalneonicexposurereducessolitarybeereproductivesuccess AgricForEnt.pdf.
- 10. Margaret Eng, et al., *Imidacloprid and Chlorpyrifos Insecticides Impair Migratory Ability in a Seed-Eating Songbird*, 7 Scientific Reports 15176, DOI:10.1038/s41598-017-15446-x (2017).
- 11. Ertl, H. et al., *Potential Impact of Neonicotinoid Use on Northern bobwhite (Colinus virginianus) in Texas: A Historical Analysis*, PLoS ONE 13:e0191100 (2018), https://doi.org/10.1371/journal.pone.0191100.
- 12. Millott et al., Field Evidence of Bird Poisonings by Imidacloprid-Treated Seeds: A Review of Incidents Reported by the French SAGIR Network from 1995 to 2014, Environ Sci Pollut Res, DOI 10.1007/s11356-016-8272y (2016).
- 13. Lopez-Antia et al., Risk Assessment of Pesticide Seed Treatment for Farmland Birds Using Refined Field Data, 136 Environmental Research 97 (2015).
- 14. EPA, FOIAOnline, Request No. EPA-HQ-2019-004044 (2019), https://foiaonline.gov/foiaonline/action/public/submissionDetails?trackingNumber=EPA-HQ-2019-004044&type=request.
- 15. NRDC, Neonicotinoid Pesticides: Potential Risks to Brain and Sperm (Jan. 6, 2021), https://www.nrdc.org/experts/jennifer-sass/neonic-pesticides-potential-risks-brain-and-

- <u>sperm#:~:text=Imidacloprid%20is%20the%20most%20common,by%20EPA%20(see%20here).</u>
- 16. EPA, Preliminary Health Effects Division Risk Assessment for Imidacloprid, at 13 (2003), https://www3.epa.gov/pesticides/chem_search/cleared_reviews/csr_PC-129099_4-Mar-03_111.pdf.
- 17. EPA, Imidacloprid: Human Health Draft Risk Assessment for Registration Review, at 11-12 (2017), https://www.regulations.gov/document?D=EPA-HQ-OPP-2008-0844-1235.
- 18. Cal. EPA, Imidacloprid: Risk Characterization Document; Dietary and Drinking Water Exposure, at ix (2006), https://www.cdpr.ca.gov/docs/risk/rcd/imidacloprid.pdf.
- 19. Cimino, et al., Effects of Neonicotinoid Pesticide Exposure on Human Health: A Systematic Review, 125(2) Environmental Health Perspectives 155 (2017), https://ehp.niehs.nih.gov/doi/full/10.1289/EHP515.
- 20. Keil, et al., Autism Spectrum Disorder, Flea and Tick Medication, and Adjustments for Exposure Misclassification: the CHARGE (CHildhood Autism Risks from Genetics and Environment) Control Study, 13 Environ. Health 3 (2014), https://pubmed.ncbi.nlm.nih.gov/24456651/.
- 21. T.G.E. Davies et al., *DDT*, *Pyrethrins*, *Pyrethroids and Insect Sodium Channels*, 59 LIFE 151, 155 (2007).
- 22. Muhammad M. Hossain, et al., *Hippocampal ER Stress and Learning Deficits Following Repeated Pyrethroid Exposure*, 143 Toxicological Sciences 220, 220 (2015).
- 23. Holly A Rogers, et al., *Bifenthrin Causes Trophic Cascade and Altered Insect Emergence in Mesocosms: Implications for Small Streams*, 50 Envtl. Sci. & Tech. 11,974, 11,974 (2016).
- 24. Stephen J. Godin, et al., *Physiologically Based Pharmacokinetic Modeling of Deltamethrin: Development of a Rat and Human Diffusion-Limited Model*, 115 Toxicological Sciences 330, 338 (2010).
- 25. Janie F. Shelton, et al. Neurodevelopmental Disorders and Prenatal Residential Proximity to Agricultural Pesticides: The CHARGE Study, 122 Children's Health 1103, 1107 (2014).
- 26. EPA, Flumethrin: Human Health Risk Assessment for the Section 3 Registration Action for Cat and Dog Collars (2016), https://www.regulations.gov/document?D=EPA-HQ-OPP-2016-0031-0005.
- 27. EPA, Flumethrin: Draft Human Health Risk Assessment for Registration Review (2018), https://www.regulations.gov/document?D=EPA-HQ-OPP-2016-0031-0027.
- 28. EPA, Flumethrin: Tier I Update Review of Humane Incidents and Epidemiology for Proposed Interim Decision, at 3-4 (2019), https://www.regulations.gov/document/EPA-HQ-OPP-2016-0031-0031.
- 29. Holly A Rogers, et al., *Bifenthrin Causes Trophic Cascade and Altered Insect Emergence in Mesocosms: Implications for Small Streams*, 50 Envtl. Sci. & Tech. 11,974, 11,974 (2016).
- 30. EPA, Preliminary Comparative Environmental Fate and Ecological Risk Assessment for the Registration Review of Eight Synthetic Pyrethroids and the Pyrethrins, (2016), https://www.regulations.gov/document/EPA-HQ-OPP-2010-0384-0045.
- 31. Nathan Donley, Center for Biological Diversity, *Toxic Concoctions: How the EPA Ignores The Dangers of Pesticide Cocktails*, 1 (2016),

- https://www.biologicaldiversity.org/campaigns/pesticides_reduction/pdfs/Toxic_concoctions.pdf.
- 32. Stanneck, et al., *The Synergistic Action of Imidacloprid and Flumethrin and Their Release Kinetics From Collars Applied for Ectoparasite Control in Dogs and Cats*, 5 Parasites & Vectors 73 (2012), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361670/.
- 33. Schulz, Applied Pesticide Toxicity Shifts Toward Plants and Invertebrates, Even in GM Crops, 372 Science 81-84 (2021), https://science.sciencemag.org/content/372/6537/81.
- 34. Marc Heller, *Farm Chemicals Turning More Toxic for Wildlife*, E&E News (Apr. 1, 2021), https://www.eenews.net/eenewspm/stories/1063729071/feed.
- 35. Jimy Tallal, *Seresto Flea Collar Linked to 1,700 Pet Deaths*, The Malibu Times (Mar. 26, 2021), http://www.malibutimes.com/news/article_36818990-8db8-11eb-9bf9-cf20318319cf.html.
- 36. Jonathan Hettinger, *Popular Flea Collar Linked to Almost 1,700 Pet Deaths. The EPA Has Issued No Warning*, USA Today (Mar. 2, 2021), https://www.usatoday.com/story/news/investigations/2021/03/02/seresto-dog-cat-collars-found-harm-pets-humans-epa-records-show/4574753001/.
- 37. NRDC, Petition to Cancel All Tetrachlorvinphos (TCVP) Pet Uses (Apr. 23, 2009), https://www.regulations.gov/document/EPA-HQ-OPP-2009-0308-0002.
- 38. EPA, Tetrachlorvinphos: Animal Incident Summary (Feb. 3, 2009), https://www.documentcloud.org/documents/20491417-epa-hq-opp-2008-0316-0018 petpoisoning.
- 39. NRDC, No More Poisons on Pets: The EPA Must Act (May 29, 2019), https://www.nrdc.org/experts/miriam-rotkin-ellman/no-more-poisons-pets-epa-must-act.
- 40. Advantage Petcare, *How Do Seresto Flea Collars Work?* (Feb. 2021), https://www.advantagepetcare.com.au/au/parasites/fleas/how-do-seresto-flea-collars-work/.
- 41. NRDC, *Nontoxic Ways to Protect Your Pet* (Jan. 22, 2016), https://www.nrdc.org/stories/nontoxic-ways-protect-your-pet.
- 42. EPA, E.I. du Pont de Nemours and Company Imprelis Order (Aug. 11, 2011), https://www.epa.gov/enforcement/e-i-du-pont-de-nemours-and-company-imprelis-order.
- 43. CBS New York, *Questions Raised About Safety of Popular Seresto Flea Collar* (Mar. 24, 2021), https://newyork.cbslocal.com/2021/03/24/seresto-pet-collar-safety-concerns/.
- 44. Jonathan Hettinger, *Amazon is Reviewing Best-Selling Seresto Flea Collar After Report of Illnesses, Deaths*, USA Today (Mar. 5, 2021), https://www.usatoday.com/story/news/investigations/2021/03/05/amazon-reviewing-seresto-flea-collar-amid-reports-illnesses-deaths/4586990001/
- 45. Jonathan Hettinger, *House Subcommittee Seeks Voluntary Recall of Seresto Flea and Tick Collars*, Midwest Center for Investigative Reporting (Mar. 18, 2021), https://investigatemidwest.org/2021/03/18/house-subcommittee-seeks-voluntarily-recall-of-seresto-flea-and-tick-collars/.